ANTENGENE

德琪醫藥有限公司
Antengene Corporation Limited

2022
INTERIM REPORT

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 6996

CONTENTS

CORPORATE INFORMATION

BOARD OF DIRECTORS

Executive Directors

Dr. Jay Mei *(Chairman and Chief Executive Officer)*
Mr. John F. Chin *(Chief Business Officer)*
Dr. Kevin Patrick Lynch *(Chief Medical Officer)*
Mr. Donald Andrew Lung *(Chief Financial Officer)*

Non-executive Directors

Dr. Kan Chen
Mr. Yilun Liu

Independent Non-executive Directors

Mr. Mark J. Alles
Ms. Jing Qian
Mr. Sheng Tang

AUDIT COMMITTEE

Mr. Sheng Tang *(Chairman)*
Mr. Mark J. Alles
Ms. Jing Qian

REMUNERATION COMMITTEE

Ms. Jing Qian *(Chairwoman)*
Dr. Jay Mei
Mr. Mark J. Alles

NOMINATION AND CORPORATE GOVERNANCE COMMITTEE

Mr. Mark J. Alles *(Chairman)*
Dr. Jay Mei
Ms. Jing Qian

AUTHORIZED REPRESENTATIVES

Dr. Jay Mei
Mr. Donald Andrew Lung

JOINT COMPANY SECRETARIES

Mr. Yang Cao
Mr. Wai Chiu Wong
(appointed on March 30, 2022)
Mr. Keith Shing Cheung Wong
(resigned on March 30, 2022)

REGISTERED OFFICE

The offices of Maples Corporate Services Limited
PO Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands

HEAD OFFICES AND PRINCIPAL PLACES OF BUSINESS IN CHINA

Suites 1206-1209, Block B
Zhongshan SOHO Plaza
1065 West Zhongshan Road
Changning District
Shanghai
PRC

Building 10, Life Science Industrial Park
1 Yunhai Road
Lihai Town, Binhai New City
Shaoxing, Zhejiang Province
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room No. 901, 9th Floor, Nan Fung Tower
88 Connaught Road Central and
173 Des Voeux Road Central
Hong Kong

PRINCIPAL SHARE REGISTRAR

Maples Fund Services (Cayman) Limited
P.O. Box 1093, Boundary Hall
Cricket Square
Grand Cayman, KY1-1102
Cayman Islands

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

FINANCIAL HIGHLIGHTS

A summary of the results of Antengene Corporation Limited (the "**Company**" or "**Antengene**", together with its subsidiaries, the "**Group**", "**we**" or "**us**") for the unaudited condensed consolidated results of the Group for six months ended June 30, 2022 (the "**Reporting Period**"), together with comparative figures for the six months ended June 30, 2021, is set out below:

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	Unaudited	Unaudited
Revenue	**53,956**	–
Other income and gains	**167,820**	18,135
Research and development costs	**(179,407)**	(135,333)
Selling and distribution expenses	**(90,377)**	(132)
Administrative expenses	**(85,878)**	(78,512)
Loss for the period	**(144,451)**	(232,995)
Total comprehensive loss for the period	**(193,816)**	(227,685)
Adjusted loss for the period*	**(126,259)**	(209,860)

* Adjusted loss for the period is not defined under the IFRS, it represents the loss for the period excluding the effect brought by equity-settled share option expense.

IFRS MEASURES:

Our revenue increased from nil for the six months ended June 30, 2021 to RMB54.0 million for the six months ended June 30, 2022, primarily attributable to the commercial launch of the first-in-class XPO1 inhibitor 希維奧®/XPOVIO® (selinexor, ATG-010) in Mainland China on May 13, 2022.

Our other income and gains increased by RMB149.7 million from RMB18.1 million for the six months ended June 30, 2021 to RMB167.8 million for the six months ended June 30, 2022, primarily attributable to the net foreign exchange gain due to the rise in the exchange rate of USD against RMB.

FINANCIAL HIGHLIGHTS

Our research and development (the "**R&D**") costs increased by RMB44.1 million from RMB135.3 million for the six months ended June 30, 2021 to RMB179.4 million for the six months ended June 30, 2022, primarily attributable to our increased drug development expenses and expansion of R&D personnel.

Our selling and distribution expenses increased by RMB90.3 million from RMB0.1 million for the six months ended June 30, 2021 to RMB90.4 million for the six months ended June 30, 2022, primarily attributable to the increase in employee costs and market development expenses.

Our administrative expenses increased by RMB7.4 million from RMB78.5 million for the six months ended June 30, 2021 to RMB85.9 million for the six months ended June 30, 2022, primarily attributable to the increase in professional fees in relation to operating and administrative activities.

As a result of the foregoing, the loss for the period decreased by RMB88.5 million from RMB233.0 million for the six months ended June 30, 2021 to RMB144.5 million for the six months ended June 30, 2022.

NON-IFRS MEASURES:

Loss for the period excluding the effect brought by equity-settled share option expense decreased by RMB83.6 million from RMB209.9 million for the six months ended June 30, 2021 to RMB126.3 million for the six months ended June 30, 2022, primarily due to the net foreign exchange gain, partially offset by our increased research and development costs, selling and distribution expenses and administrative expenses.

BUSINESS HIGHLIGHTS

During the six months ended June 30, 2022, and as at the date of this report, significant advancement has been made with respect to our product pipeline and business operations:

LATE-STAGE ASSETS:

- Selinexor (ATG-010, XPOVIO®, Greater China brand name 希維奧®, first-in-class XPO1 inhibitor)
    - In March 2022, XPOVIO® (selinexor, ATG-010) has been granted approval from the Health Sciences Authority ("**HSA**") in Singapore for three indications: in combination with bortezomib and dexamethasone for treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (rrMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory), and as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) who have received at least two prior lines of treatment and are not eligible for haematopoietic cell transplant.
    - In March 2022, Australia's Therapeutic Goods Administration (TGA) has registered XPOVIO® (selinexor, ATG-010) for two indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with MM who have received at least one prior therapy; and (2) in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product, and an anti-CD38 monoclonal antibody.
    - In April 2022, the first patient has been dosed in the single-arm Phase Ib Study (the "**MATCH**" study), designed to evaluate the safety, tolerability and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with onatasertib (ATG-008) for the treatment of rrDLBCL.

BUSINESS HIGHLIGHTS

- In May 2022, the first patient has been dosed in the single-arm Phase I/II Study (the "**SWATCH**" study), designed to evaluate the safety, tolerability and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with the R2 regimen of lenalidomide plus rituximab for the treatment of rrDLBCL and relapsed/refractory indolent non-Hodgkin lymphoma (rriNHL).

- In May 2022, XPOVIO® (selinexor, ATG-010) has officially entered multiple hospitals, online-hospitals, and direct-to-patient (DTP) pharmacies in mainland China and widely prescribed in the country for the first time.

- In May 2022, the 2022 CSCO Guidelines has added multiple XPOVIO® (selinexor, ATG-010) regimens for the treatment of rrMM and rrDLBCL for the Diagnosis and Treatment of Hematologic Malignancies and 2022 Guidelines for the Diagnosis and Treatment of Lymphomas.

- In June 2022, we entered into a clinical trial collaboration with BeiGene, Ltd. ("**BeiGene**") to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma.

- Onatasertib (ATG-008, mTORC1/2 inhibitor)

  - In April 2022, we announced that a clinical trial abstract related to ATG-008 (onatasertib) has been selected for presentation in the 2022 American Society of Clinical Oncology Annual Meeting (2022 ASCO). The abstract highlights initial results of the Phase I/II TORCH-2 study evaluating ATG-008 (onatasertib) in combination with toripalimab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

BUSINESS HIGHLIGHTS

OTHER CLINICAL STAGE ASSETS:

- Eltanexor (ATG-016, second generation XPO1 inhibitor)

  In March 2022, China's National Medical Products Administration ("**NMPA**") has approved a Phase II open-label study designed to evaluate the safety, tolerability and efficacy of the next-generation selective inhibitor of nuclear export (SINE) compound ATG-016 in patients with high-risk myelodysplastic syndromes (MDS).

- ATG-019 (dual PAK4/NAMPT inhibitor)

  The Phase I safety and tolerability study of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (the "**TEACH trial**") in mainland China and Taiwan is ongoing.

- ATG-017 (ERK1/2 inhibitor)

  The Phase I dose-escalation study of ATG-017 for the treatment of advanced solid tumors and hematologic malignancies in Australia (the "**ERASER trial**") is ongoing.

- ATG-101 (PD-L1/4-1BB bispecific antibody)

  In March 2022, China NMPA has approved the Phase I study of ATG-101, a novel PD-L1/4-1BB bispecific antibody (the PROBE-CN study), for the treatment of advanced/metastatic solid tumors and B-cell non-Hodgkin lymphoma (B-NHL). In August 2022, we announced the first patient dosed in PROBE-CN trial.

- ATG-037 (CD73 inhibitor)

  In February 2022, the Bellberry Human Research Ethics Committee (HREC) in Australia approved our clinical trial application of the Phase I trial of ATG-037 in patients with locally advanced or metastatic solid tumors (the "**STAMINA trial**").

  In June 2022, the first patient has been dosed in the STAMINA trial to evaluate ATG-037 as a monotherapy or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors in Australia.

- ATG-018 (ATR inhibitor)

  In June 2022, we received approval by the HREC in Australia to initiate the Phase I Trial of ATG-018 in patients with advanced solid tumors and hematologic malignancies (the "**ATRIUM trial**").

BUSINESS HIGHLIGHTS

PRE-CLINICAL STAGE ASSETS:

We made steady progress in our pre-clinical pipeline assets – ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-027 (B7H3/PD-L1 bispecific antibody), ATG-032 (LILRB antibody), ATG-041 (Axl-Mer inhibitor) and ATG-012 (KRAS inhibitor).

BUSINESS DEVELOPMENT AND OTHER KEY ACTIVITIES:

- We are leveraging our combinatory and complementary R&D strategy and through our strong R&D capabilities and strategic approach to developing novel therapies, to continue to realize our vision of treating patients beyond borders and improving their lives in discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies. Moving forward, we will focus on our dual engine strategy by pursuing in-house discovery as well as strategic partnerships to accelerate value creation of the Company.

- In June 2022, we entered in to a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma.

- With the official entrance of XPOVIO® (selinexor, ATG-010) to multiple hospitals, online-hospitals, and DTP pharmacies in mainland China and expected approvals across multiple APAC markets towards the second half of 2022, Antengene has continued to build up its experienced commercial team across China and the APAC region with plans to grow its commercial organization to up to 200 full time employees in functions including in-house marketing, field force, pricing and market access by the end of 2022.

MANAGEMENT DISCUSSION AND ANALYSIS

OUR VISION

Our vision is to treat patients beyond borders and transform their lives by discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

OVERVIEW

Started operations in 2017, we are a commercial-stage Asia-Pacific ("**APAC**") biopharmaceutical company focused on innovative oncology medicines. We distinguish ourselves through our strong R&D capabilities and strategic approach to developing novel oncology therapies.

We have strategically designed and built a highly selective pipeline of 15 drug assets focused on oncology, including five with APAC rights and ten with global rights. We employ a combinatory and complementary R&D strategy to maximise the potential of our pipeline assets which are synergistic to each other. We have obtained NDA approvals from the health authorities of mainland China, South Korea, Singapore, and Australia; NDA approvals from Hong Kong and Taiwan are expected in the second half of 2022. We also obtained IND approvals or initiated five additional registrational clinical trials of our lead asset, selinexor, in rrMM, rrDLBCL, endometrial cancer and myelofibrosis in mainland China.

XPOVIO® (selinexor, ATG-010) is a first-in-class and only-in-class orally available XPO1 inhibitor and ATG-008 (onatasertib) is a potentially first-in-class mTORC1/2 inhibitor. Among our clinical stage assets, we also have two other drug candidates in the validated selective inhibitor of nuclear export ("**SINE**") class, namely ATG-016 (eltanexor) and ATG-527 (verdinexor), which feature differentiated profiles that allow us to target a wide range of indications through both mono-and combination therapies. ATG-031 is an anti-CD24 monoclonal antibody, and CD24 is a signaling protein similar to CD47, which can bind to Siglec-10 on the tumor associated macrophages to activate the inhibitory signaling pathway mediated by SHP-1/SHP-2. ATG-017 is a potent and selective ERK1/2 inhibitor with best-in-class potential for the treatment of various hematological malignancies and solid tumors driven by the aberrant RAS/MAPK pathway. ATG-101 is a novel, PD-L1/CD137 (4-1BB) bispecific antibody being developed for the treatment of hematological malignancies and solid tumors. ATG-037 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73. It can reactivate antitumor immunity by inhibiting the highly immunosuppressive adenosine pathway.

Product Pipeline

We have a pipeline of 15 drug candidates that focus on cancer treatment and range from pre-clinical stage to late-stage clinical programs. The following table summarizes our pipeline and the development status of each candidate in the regions noted in the chart below in the "Antengene Rights" column:

Assets	Target (Modality)	Regimen	Pre-clinical / Phase I / Phase II / Phase III / NDA / Commercialization	Antengene Rights	Partner
ATG-010 (Selinexor)[1,2]	XPO1 (Small molecule)	R/R Multiple Myeloma	Combo with dexamethasone *(MARCH) – Antengene's Registrational Trial in Mainland China* — *Mainland China NDA approved*	APAC[2]	Karyopharm Therapeutics; ANTENGENE
			Combo with dexamethasone *(STORM) – Partner's Pivotal Trial in the US* — *US, EU, SK, SG & AU NDA approved*		
			Combo with bortezomib and dexamethasone *(BENCH) – Antengene's Registrational Trial in Mainland China* ★		
			Combo with bortezomib and dexamethasone *(BOSTON) – Partner's Pivotal Trial in the US* — *US, EU, SG & AU s NDA approved*		
			Combo with IMID/PI/CD38 mAb and dexamethasone *(STOMP)*		
		R/R Diffuse Large B-cell Lymphoma	Monotherapy *(SEARCH) – Antengene's Registrational Trial in Mainland China* ★		
			Monotherapy *(SADAL) – Partner's Pivotal Trial in the US* — *US , SK & SG s NDA approved*		
			Combo with R-GDP *(DLBCL-030)* ★		
		R/R NHL	Combo with lenalidomide + rituximab *(SWATCH)*		
		R/R T-cell & NK-cell Lymphoma	Combo with ICE/GemOx/tislelizumab *(TOUCH)*		
		Myelofibrosis	Monotherapy *(MF 035)* ★		
		Maintenance Therapy for Endometrial Cancer	Monotherapy *(SIENDO)*		
		Advanced Liposarcoma	Monotherapy *(SEAL)*		
		Recurrent Glioblastoma	Monotherapy *(KING)*		
		ND & Recurrent Glioblastoma	Monotherapy *(GBM-029)*		
ATG-016 (Eltanexor)[2]	XPO1 (Small molecule)	R/R MDS	Monotherapy *(HATCH)*		
			Monotherapy *(KCP-8602-801)* ★		
		Advanced Solid Tumors	Monotherapy *(REACH)* — CRC PrC		
ATG-008 (Onatasertib)[3]	mTORC1/2 (Small molecule)	2L+ HBV+ Hepatocellular Carcinoma	Monotherapy *(TORCH)*	APAC[3]	Celgene | Bristol Myers Squibb Company; ANTENGENE
		Advanced Solid Tumors and Hepatocellular Carcinoma	Combo with toripalimab *(TORCH-2)**		
		R/R Diffuse Large B-cell Lymphoma	Combo with ATG-010 *(MATCH)*		
ATG-527 (Verdinexor)[2]	XPO1 (Small molecule)	Lupus, Anti-viral	Monotherapy *(EVOLVE)*	APAC[2]	Karyopharm Therapeutics; ANTENGENE
ATG-019 (KPT-9274)[2]	PAK4/NAMPT (Small molecule)	Advanced Solid Tumors & NHL	Monotherapy ± niacin *(TEACH)*		
ATG-017 (Tizaterkib)[4]	ERK1/2 (Small molecule)	R/R Hem/Onc	Monotherapy ± nivolumab *(ERASER)*	Global	ANTENGENE
ATG-101[5]	PD-L1/4-1BB (Bispecific)	Hem/Onc	Monotherapy *(PROBE & PROBE-CN)*		
ATG-037[6]	CD73 (Small molecule)	Hem/Onc	Monotherapy ± IO *(STAMINA)*		
ATG-018	ATR (Small molecule)	Hem/Onc	Monotherapy *(ATRIUM)*		
ATG-022	Claudin 18.2 (ADC)	Onc	Monotherapy *(CLINCH)*		
ATG-031	CD24 (mAb)	Hem/Onc	Monotherapy		
ATG-012	KRAS (Small molecule)	Onc	Monotherapy		
ATG-027	B7H3/PD-L1 (Bispecific)	Hem/Onc	Monotherapy		
ATG-032	LILRB (mAb)	Hem/Onc	Monotherapy		
ATG-041	Axl-Mer (Small molecule)	Hem/Onc	Monotherapy		

Antengene Trials[7] | Partner Trials[8] | Global Trials in Collaboration with Partner | ★ Registrational Trial in China

[1] IgNDA approved by US FDA, China NMPA, Australia TGA, South Korea MFDS and Singapore HSA; China Hong Kong and China Taiwan NDA submissions are completed;
[2] Licensed from Karyopharm and Antengene has rights for Greater China (mainland China, Hong Kong, Taiwan, Macau), Australia, New Zealand, South Korea, and the ASEAN Countries;
[3] Licensed from Celgene (BMS) and Antengene has rights for Greater China, South Korea, Singapore, Malaysia, Indonesia, Vietnam, Laos, Cambodia, the Philippines, Thailand and Mongolia;
[4] Licensed from AstraZeneca and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017;
[5] Licensed from Origincell and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-101;
[6] Licensed from Califirnia Biosciences and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-037
[7] Most advanced trial status in Antengene territories and the trials are responsible by Antengene;
[8] Most advanced trial status in partner territories in the rest of the world and the trials are conducted by our licensing partners

* Investigator-initiated trials; R/R = relapsed/refractory; ND = newly diagnosed; MDS = myelodysplastic syndrome; CRC = colorectal cancer; PrC = prostate cancer; CAEBV = chronic active Epstein-Barr virus; NHL = non-Hodgkin lymphoma; Hem/Onc = hematological malignancies and solid tumors; SK= South Korea; R-GDP: Rituximab, Gemcitabine, Dexamethasone & Cisplatin; in GBM-029 trial, the combination regimen is with standard of care (SoC) therapy for newly diagnosed glioblastoma or recurrent glioblastoma, including radiation therapy, temozolomide, lomustine, bevacizumab, tumor treating fields, or carmustine

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

We have made steady progress with regard to our pipeline assets in the first half of 2022. We have obtained NDA approvals in Australia and Singapore in the first half of 2022. We are expecting NDA approvals in Hong Kong and Taiwan for the treatment of rrMM and rrDLBCL in the second half of 2022.

Late-stage Product Candidates

ATG-010 (selinexor, XPO1 inhibitor)

ATG-010 (selinexor), one of our Core Products, is a first-in-class, orally available SINE compound being developed for the treatment of various hematological malignancies and solid tumors. We obtained exclusive rights from Karyopharm Therapeutics Inc. ("**Karyopharm**") for the development and commercialization of selinexor in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries.

Our licensing partner, Karyopharm, obtained approval through the U.S. FDA's Accelerated Approval Program on July 3, 2019 for XPOVIO® (selinexor, ATG-010) in combination with low-dose dexamethasone for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents (IMiDs) and an anti-CD38 mAb.

On June 22, 2020, XPOVIO® (selinexor, ATG-010) received accelerated approval from the U.S. FDA for the treatment of adult patients with rrDLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. On December 18, 2020, the U.S. FDA approved XPOVIO® (selinexor, ATG-010) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In May 2022, XPOVIO® (selinexor, ATG-010) has officially entered multiple hospitals, online-hospitals, and DTP pharmacies in mainland China and widely prescribed in the country for the first time.

In May 2022, the 2022 CSCO Guidelines has added multiple XPOVIO® (selinexor, ATG-010) regimens for the treatment of rrMM and rrDLBCL for the Diagnosis and Treatment of Hematologic Malignancies and 2022 Guidelines for the Diagnosis and Treatment of Lymphomas. In addition, uses of XPOVIO® (selinexor, ATG-010) for MM patients with first relapse or multiple relapses were incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China (2022 revision). This is the first time that XPOVIO® (selinexor, ATG-010) has been included in the guidelines.

Several late-stage clinical studies are underway for XPOVIO® (selinexor, ATG-010) in mainland China:

A Phase II registrational clinical trial as monotherapy in rrDLBCL (the "**SEARCH**" trial). We dosed the first patient in SEARCH trial in 2020.

A Phase III registrational clinical trial in combination with bortezomib and low-dose dexamethasone in rrMM (the "**BENCH**" trial). We received IND approval from the NMPA at the end of 2020 and dosed the first patient in July 2021.

A Phase II/III registrational clinical trial in combination with rituximab, gemcitabine, dexamethasone and cisplatin ("**R-GDP**") in rrDLBCL, which is part of the global pivotal trial (XPORT-DLBCL-030) led by Karyopharm. We received IND approval from the NMPA in January 2021 and dosed the first patient in December 2021.

A Phase II registrational clinical trial as monotherapy for patients with myelofibrosis, which is part of the global pivotal trial (the "**MF 035**" trial) led by Karyopharm. We received IND approval from China NMPA in August 2021.

To further explore the clinical potential of selinexor in cancer treatment, we also initiated early signal detection studies including Phase Ib clinical trial in combination with ifosfamide, carboplatin and etoposide ("**ICE**"), gemcitabine and oxaliplatin ("**GemOx**") or tislelizumab in the treatment of T-cell and NK/T-cell lymphoma patients, Phase Ib clinical trial in combination with ATG-008 (onatasertib) for the treatment of rrDLBCL and Phase I/II S-R2 in rriNHL.

In June 2022, we entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma.

In April 2022, the first patient was dosed in the single-arm Phase Ib Study (the **"MATCH" study**), designed to evaluate the safety, tolerability and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with onatasertib (ATG-008) for the treatment of rrDLBCL.

In May 2022, the first patient was dosed in the SWATCH Study, designed to evaluate the safety, tolerability and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with the R^2 regimen of lenalidomide plus rituximab for the treatment of rrDLBCL and rriNHL.

In March 2022, XPOVIO® (selinexor, ATG-010) has been granted approval from the HSA in Singapore for three indications: (1) in combination with bortezomib and dexamethasone for treatment of adult patients with MM who have received at least one prior therapy; (2) in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory); and (3) as a monotherapy for the treatment of adult patients with rrDLBCL who have received at least two prior lines of treatment and are not eligible for haematopoietic cell transplant.

In March 2022, Australia's TGA has registered XPOVIO® (selinexor, ATG-010) for two indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and (2) in combination with dexamethasone for the treatment of adult patients with rrMM who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product, and an anti-CD38 monoclonal antibody.

WE MAY NOT BE ABLE TO ULTIMATELY MARKET ATG-010 (SELINEXOR) SUCCESSFULLY.

ATG-008 (onatasertib, mTORC1/2 inhibitor)

ATG-008 (onatasertib), one of our Core Products. We obtained an exclusive license from Celgene (now BMS) for the development and commercialization of onatasertib in mainland China, Hong Kong, Taiwan, Macau and selected APAC markets. We initiated a Phase I/II study of onatasertib in combination with toripalimab (anti-PD-1 antibody) in mainland China, and in February 2021, we dosed the first patient in the dose expansion cohort. In April 2022, we announced that a clinical trial abstract related to ATG-008 (onatasertib) has been selected for presentation in the 2022 American Society of Clinical Oncology Annual Meeting (2022 ASCO). The abstract highlighted initial results of the Phase I/II TORCH-2 study evaluating ATG-008 (onatasertib) in combination with toripalimab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors. Particularly, among the 5 efficacy evaluable patients in the cervical cancer cohort, 1 patient with negative PD-L1 expression experienced a complete response (CR), and 3 patients experienced a partial response (PR); all responses were confirmed.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ATG-008 (ONATASERTIB) SUCCESSFULLY.

Other Clinical Candidates

Eltanexor (ATG-016, second generation XPO1 inhibitor) – We obtained exclusive rights from Karyopharm for the development and commercialization of eltanexor in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries. We received IND approval of a Phase II open-label study designed to evaluate the safety, tolerability and efficacy of ATG-016 in patients with high-risk myelodysplastic syndromes (MDS) from NMPA in mainland China in March 2022. In addition, we have two studies ongoing in mainland China: a Phase I/II, open-label study to investigate the PK, safety, and efficacy of eltanexor (ATG-016) monotherapy in IPSS-R intermediate risk and above MDS patients after failure of HMA-based therapy (the "**HATCH trial**") and a Phase Ib/II open-label, multi-center, dose finding study to assess the safety, PK, and preliminary efficacy of eltanexor (ATG-016) monotherapy in patients with advanced solid tumors (the "**REACH trial**").

Verdinexor (ATG-527, third generation XPO1 inhibitor) – We obtained exclusive rights from Karyopharm for the development and commercialization of verdinexor in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries. Verdinexor will be developed in non-oncological indications. Having completed a Phase I evaluation in healthy volunteers, a Phase II, multi-center, signal-seeking basket study protocol is now being developed in Australia that will evaluate the ability of verdinexor to suppress viral load across a range of chronic human viral infections.

ATG-019 (dual PAK4/NAMPT inhibitor) – We obtained exclusive rights from Karyopharm for the development and commercialization of ATG-019 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Australia, New Zealand and ASEAN countries. In 2020, we dosed the first patient in a Phase I solid tumor and lymphoma clinical study in Taiwan. Subsequently, we received IND approval from the NMPA in mainland China of a Phase I clinical trial to evaluate safety and tolerability of ATG-019 in patients with advanced solid tumors or non-Hodgkin's lymphoma in May 2021.

ATG-017 (ERK1/2 inhibitor) – We obtained exclusive rights from AstraZeneca AB ("**AstraZeneca**") for the development and commercialization of ATG-017 worldwide. In 2020, we dosed the first patient in a Phase I clinical study in Australia. The dose-escalation study of ATG-017 for the treatment of advanced solid tumors and hematologic malignancies in Australia (the "**ERASER trial**") is ongoing.

ATG-101 (PD-L1/4-1BB bispecific antibody) – The dose-escalation study of ATG-101 for the treatment of metastatic/advanced solid tumors and B-NHL in Australia (the "**PROBE trial**") is ongoing. In March 2022, China NMPA approved the IND application for a Phase I study of ATG-101 in mainland China (the "**PROBE-CN**" trial). In August 2022, we dosed the first patient in mainland China.

ATG-037 (CD73 inhibitor) – The HREC in Australia approved our clinical trial application of the Phase I trial of ATG-037 in patients with locally advanced or metastatic solid tumors (the "**STAMINA**" trial) in February 2022. We dosed the first patient in June 2022.

ATG-018 (ATR inhibitor) – In June 2022, we received approval by the HREC in Australia to initiate the Phase I Trial of ATG-018 in patients with advanced solid tumors and hematologic malignancies (the "**ATRIUM trial**"). We dosed the first patient in August 2022.

Pre-clinical Candidates

ATG-022 (Claudin 18.2 antibody-drug conjugate) – We are conducting preclinical studies to support IND/CTA applications of ATG-022 and plan to submit the applications by the end of this year.

ATG-031 (CD24 antibody) – We are conducting preclinical studies to support IND/CTA applications of ATG-031 and plan to submit the applications in 2023.

ATG-027 (B7H3/PD-L1 bispecific antibody) – We are conducting preclinical studies to support IND/CTA applications of ATG-027 and plan to submit the applications in 2023.

ATG-032 (LILRB antibody) – We are conducting preclinical studies to support IND/CTA applications of ATG-032.

ATG-041 (Axl-Mer inhibitor) – We are conducting preclinical studies to support IND/CTA applications of ATG-041.

ATG-012 (KRAS inhibitor) – We are conducting preclinical studies to support IND/CTA applications of ATG-012 and plan to submit the applications in 2023.

RESEARCH AND DEVELOPMENT

We focus on R&D of therapeutic strategies for the treatment of cancer. We seek to optimize the drug development process of each of our assets to fully unlock their therapeutic potential and maximise their clinical and commercial value. We have adopted a differentiated combinatory and complementary R&D approach to build a pipeline of first/best-in-class assets with synergistic profiles.

As at June 30, 2022, we have nineteen ongoing clinical studies in mainland China, South Korea, Taiwan and Australia with eight of our pipeline assets, including ATG-010 (selinexor, XPO1 inhibitor), ATG-008 (onatasertib, mTORC1/2 inhibitor), ATG-016 (eltanexor, XPO1 inhibitor), ATG-019 (dual PAK4/NAMPT inhibitor), ATG-017 (ERK1/2 inhibitor), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-037 (CD73 inhibitor) and ATG-018 (ATR inhibitor). We are enrolling patients for five registrational Phase II or Phase III studies in mainland China in rrMM, rrDLBCL, myelofibrosis and myelodysplastic syndrome, respectively. We have received NDA approvals for XPOVIO® (selinexor, ATG-010) in mainland China and South Korea in 2021, and in Singapore and Australia in March 2022. We expect to receive NDA approvals from Hong Kong Department of Health, and Taiwan Food and Drug Administration in the second half of 2022.

Our adjusted R&D costs (non-IFRS measure) were approximately RMB170.0 million and RMB125.9 million for the six months ended June 30, 2022 and 2021 respectively. As at June 30, 2022, we had filed 5 patent applications in mainland China, and 7 international applications under the Patent Cooperation Treaty (PCT) for material intellectual properties, all of which are pending.

BUSINESS DEVELOPMENT

In June 2022, we entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of XPOVIO® (selinexor, ATG-010) in combination with BeiGene's anti-PD-1 checkpoint inhibitor, tislelizumab. This multi-center, open-label Phase I/II trial will evaluate the investigational combination as a potential treatment option for patients with T and NK-cell lymphoma.

IMPACT OF THE COVID-19 OUTBREAK

Since the outbreak of the novel coronavirus ("**COVID-19**") in early 2020, the Company has adopted immediate measures to maintain effective and high-quality level of operation. Although we experienced some delays in the patient enrollment process and data entry for certain of our clinical trials in China at the beginning of the COVID-19 pandemic, there has not been any material disruption of our ongoing clinical trials. The COVID-19 pandemic has not caused any early termination of our clinical trials or necessitated removal of any patients enrolled in the clinical trials.

In addition, the launch of XPOVIO® (selinexor, ATG-010) in mainland China was delayed because of government lock-down measures in the second quarter of 2022. However, we managed to launch XPOVIO® (selinexor, ATG-010) even during the height of the Shanghai lockdown in mid May.

We have not experienced and currently do not expect any material regulatory delays in respect of our clinical trials or any long-term impact on our operation or deviation from our overall development plans due to the COVID-19 pandemic. We have not experienced any material impact from COVID-19 on the progress, status or filing update of our ongoing research and clinical activities and commercialization.

EVENTS AFTER THE REPORTING PERIOD

In July 2022, we entered into a pre-clinical research collaboration with Celularity Inc. (NASDAQ: CELU) ("**Celularity**"), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies. Antengene and Celularity will evaluate the potential therapeutic synergy of combining our bispecific antibody with Celularity's cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy platform.

In August 2022, we dosed the first patient in the Phase I PROBE-CN trial to evaluate ATG-101 as a monotherapy in patients with advanced/metastatic solid tumors or B-cell non-Hodgkin lymphoma (B-NHL) in mainland China.

In August 2022, we entered into an agreement with a limited liability company established in the PRC (the "**Contractor**") at a consideration of RMB245,524,402. The Contractor is wholly-owned by Zhejiang Zhongnan Holding Group Co., Ltd. (浙江中南控股集團有限公司). The Contractor will undertake the construction work of our Hangzhou factory, a construction site at Biopharma Town, Xiasha Economic and Technological Development Zone, Qiantang District, Hangzhou City (杭州市錢塘區下沙經濟技術開發區醫藥港小鎮) with a total area of approximately 113,911.97 sq.m., which comprises an above-ground construction area of approximately 93,964.52 sq.m. and an underground construction area of approximately 19,947.45 sq.m. (the "**Construction Project**"). For further details, please refer to the announcement of the Company dated August 8, 2022.

In August 2022, we dosed the first patient in the Phase I ATRIUM trial to evaluate ATG-018 as a monotherapy in patients with advanced solid tumors and hematologic malignancies in Australia.

In August 2022, XPOVIO® (selinexor, ATG-010) in combination with dexamethasone (Xd) has been Pharmaceutical Benefits Scheme (PBS) listed for the treatment of adult patients with rrMM who have received at least four prior lines of therapy and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti-CD38 monoclonal antibody (penta-refractory) in Australia.

FUTURE AND OUTLOOK

Leveraging our combinatory and complementary R&D strategy and through our strong R&D capabilities and strategic approach in developing novel therapies, we continue to realize our vision of treating patients beyond borders and improving their lives in discovering, developing and commercializing global first-in-class, only-in-class and/or best-in-class therapies.

We will continue to advance the clinical development of our eight clinical stage products in multiple therapeutic areas, and continue to implement our dual-engine approach of external partnerships and internal discovery to build up a pipeline focusing on the key oncogenic pathways, tumor microenvironment and tumor associated antigens globally and across the APAC region. We also intend to continue implementing our complementary approach to develop the in-licensed assets for additional indications to maximise their commercial potential.

We have received NDA approvals for XPOVIO® (selinexor, ATG-010) in mainland China and South Korea in 2021, and in Singapore and Australia in March 2022. Looking into the second half of 2022, we further expect to receive approvals for selinexor (ATG-010) in Hong Kong and Taiwan in the second half of 2022. We will also advance at least one of our pre-clinical novel assets into the IND stage.

With the expected NDA approvals mentioned above and building upon our core commercial leadership team with experience in multiple successful launches of top hematology products globally, including the APAC region and China, we will continue to build out our commercial team in preparation for the commercialization of XPOVIO® (selinexor, ATG-010) in Greater China and the rest of APAC region to address unmet medical needs in our territories. In addition to the launch in Australia and Singapore in early 2022, we have also officially launched XPOVIO® (selinexor, ATG-010) in mainland China in May 2022 with strong KOL engagement and support for XPOVIO® as a new innovative therapy with a unique mechanism of action.

FINANCIAL REVIEW

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
REVENUE	**53,956**	–
Cost of sales	**(8,705)**	–
Gross profit	**45,251**	–
Other income and gains	**167,820**	18,135
Research and development costs	**(179,407)**	(135,333)
Selling and distribution expenses	**(90,377)**	(132)
Administrative expenses	**(85,878)**	(78,512)
Other expenses	**(1,505)**	(36,537)
Finance costs	**(355)**	(616)
LOSS BEFORE TAX	**(144,451)**	(232,995)
Income tax expense	**–**	–
LOSS FOR THE PERIOD	**(144,451)**	(232,995)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	**(193,816)**	(227,685)
Non-IFRS measures:		
Adjusted loss for the period	**(126,259)**	(209,860)

Revenue. Our revenue increased from nil for the six months ended June 30, 2021 to RMB54.0 million for the six months ended June 30, 2022, primarily attributable to the commercial launch of the first-in-class XPO1 inhibitor 希維奧®/XPOVIO® (selinexor, ATG-010) in Mainland China on May 13, 2022.

Other Income and Gains. Our other income and gains increased by RMB149.7 million from RMB18.1 million for the six months ended June 30, 2021 to RMB167.8 million for the six months ended June 30, 2022, primarily attributable to the net foreign exchange gain of RMB144.4 million for the six months ended June 30, 2022 due to the rise in the exchange rate of USD against RMB, as compared to the net foreign exchange loss of RMB35.8 million for the six months ended June 30, 2021.

Other Expenses. Our other expenses decreased by RMB35.0 million from loss of RMB36.5 million for the six months ended June 30, 2021 to loss of RMB1.5 million for the six months ended June 30, 2022. The decrease was mainly attributable to the absence of RMB35.8 million of net foreign exchange loss that was recorded for the six months ended June 30, 2021.

Research and Development Costs. Our research and development costs increased by RMB44.1 million from RMB135.3 million for the six months ended June 30, 2021 to RMB179.4 million for the six months ended June 30, 2022. This increase was primarily attributable to the combined impact of (i) an increase in employee costs of R&D personnel of RMB25.6 million from RMB34.1 million for the six months ended June 30, 2021 to RMB59.7 million for the six months ended June 30, 2022, mainly due to our R&D headcount expansion; and (ii) an increase of RMB30.2 million in our drug development expenses paid to contract research organisations ("**CRO(s)**"), contract development and manufacturing organisations ("**CDMO(s)**") and site management organisations ("**SMOs**") in line with our increased R&D activities.

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
Employee costs	**59,679**	34,142
– Equity-settled share option expense	**9,417**	9,433
Depreciation and amortization	**3,048**	489
Licensing fees	**13,213**	19,838
Drug development expenses	**94,608**	64,429
Professional fees	**4,345**	12,598
Others	**4,514**	3,837
Total	**179,407**	135,333

Selling and distribution expenses. Our selling and distribution expenses increased by RMB90.3 million from RMB0.1 million for the six months ended June 30, 2021 to RMB90.4 million for the six months ended June 30, 2022, primarily attributable to the increase in employee costs and market development expenses, due to the expansion of commercial organization and pre-launch and launch activities carried out for our lead product, selinexor, in Greater China and other countries/regions.

The tables below set forth the components of our selling and distribution expenses by geography and nature for the periods indicated:

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
Greater China	**73,891**	132
Other countries/regions	**16,486**	–
Total	**90,377**	132

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
Employee costs	**46,775**	–
– Equity-settled share option expense	**2,301**	–
Market development expenses	**41,433**	–
Depreciation and amortization	**1,271**	–
Others	**898**	132
Total	**90,377**	132

Administrative Expenses. Our administrative expenses increased by RMB7.4 million from RMB78.5 million for the six months ended June 30, 2021 to RMB85.9 million for the six months ended June 30, 2022. This increase was primarily attributable to the increase in professional fees for legal, consulting, recruiting, translation and other services in relation to operating and administrative activities.

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
Employee costs	**43,896**	49,593
– Equity-settled share option expense	**6,474**	13,702
Professional fees	**23,539**	15,565
Depreciation and amortization	**6,531**	3,881
Others	**11,912**	9,473
Total	**85,878**	78,512

NON-IFRS MEASURES

To supplement the Group's unaudited condensed consolidated financial statements, which are presented in accordance with the IFRS, the Company also uses adjusted loss for the period and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The Company believes that these adjusted measures provide useful information to shareholders and potential investors in understanding and evaluating the Group's consolidated results of operations in the same manner as they help the Company's management.

Adjusted loss for the period represents the loss for the period excluding the effect of equity-settled share option expense. The term adjusted loss for the period is not defined under the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, the Group's results of operations or financial condition as reported under IFRS. The Company's presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, the Company believes that this and other non-IFRS measures are reflections of the Group's normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of the Group's operating performance, and thus, facilitate comparisons of operating performance from period to period and company to company to the extent applicable.

The table below sets forth a reconciliation of the loss to adjusted loss during the periods indicated:

	For the six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
Loss for the period	**(144,451)**	(232,995)
Added:		
Equity-settled share option expense	**18,192**	23,135
Adjusted loss for the period	**(126,259)**	(209,860)

EMPLOYEES AND REMUNERATION POLICIES

The following table sets forth a breakdown of our employees as at June 30, 2022 by function:

Function	Number of employees	% of total number of employees
General and Administrative	77	20.1
Research and Development	118	30.8
Commercialization	168	43.9
Manufacturing	20	5.2
Total	**383**	**100.0**

As at June 30, 2022, we had 336 employees in China and 47 employees in overseas. Our employees' remuneration comprises salaries, bonuses, employee provident fund and social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees.

Moreover, a wide range of on-the-job training and capacity-building activities were organized to help all employees to develop professional clinical knowledge and strengthen their management skills. To ensure our employees are well-equipped to deliver their work, we help new employees quickly fit into the Company by offering orientation training and on-the-job training from their entry so they can familiarize themselves with Antengene and their work duties. In addition, each new employee will also be assigned a mentor to help them adapt to the new working environment and explore their personal development and career aspirations.

LIQUIDITY AND FINANCIAL RESOURCES

As at June 30, 2022, our cash and bank balances were RMB2,151.0 million, as compared to RMB2,274.8 million as at December 31, 2021. The decrease was mainly due to expenses of operating activities and funds from disposal of financial assets at fair value through profit or loss.

As at June 30, 2022, the Group's cash and bank balances were held mainly in USD and RMB.

As at June 30, 2022, the current assets of the Group were RMB2,241.7 million, including cash and bank balances of RMB2,151.0 million, and other current assets of RMB90.7 million. As at June 30, 2022, the current liabilities of the Group were RMB200.5 million, including other payables and accruals of RMB174.5 million and other current liabilities of RMB26.0 million.

Current Ratio

Current ratio is calculated using current assets divided by current liabilities and multiplied by 100%. As at June 30, 2022, our current ratio was 1,117.9% (as at December 31, 2021: 1,513.9%).

Gearing Ratio

Gearing ratio is calculated using total liabilities divided by total assets and multiplied by 100%. As at June 30, 2022, our gearing ratio was 9.1% (as at December 31, 2021: 6.4%).

OTHER FINANCIAL INFORMATION

Significant Investments, Material Acquisitions and Disposals

As at June 30, 2022, we did not hold any significant investments. For the six months ended June 30, 2022, we did not have material acquisitions or disposals of subsidiaries, associates and joint ventures.

Future Plans for Material Investments or Capital Assets

Save as the Construction Project as disclosed in page 16 of this report which will be financed by the Group's internal resources, bank facilities or a combination of both, we did not have any other concrete plans for material investments or capital assets as at June 30, 2022.

Foreign Exchange Risk

We have transactional currency exposures. The majority of our bank balances and interest receivables are denominated in foreign currencies and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Contingent Liabilities

As at June 30, 2022, we did not have any material contingent liabilities.

Pledge or charge of assets

There was no pledge or charge of the Group's assets as at June 30, 2022.

DIRECTORS AND SENIOR MANAGEMENT

EXECUTIVE DIRECTORS

Dr. Jay Mei (梅建明), M.D., Ph.D., aged 57, was appointed as a Director on August 28, 2018. He was re-designated as an Executive Director and appointed as the Chairman of the Board and the Chief Executive Officer of our Company (the "**CEO**") on August 18, 2020. Dr. Mei has been one of the key management members of our Group and has been actively involved in the business, strategy and operational management of our Group since its establishment.

Dr. Mei has over 30 years of experience in clinical research and development of oncology therapeutics globally and has successfully led the development of multiple oncology products. He has published over 70 publications and holds multiple patents jointly with other investors.

Prior to founding Antengene, Dr. Mei served as an Executive Director of the clinical development department at Celgene (now part of Bristol-Myers Squibb (a company listed on the New York Stock Exchange with stock code BMY.NYSE)) from October 2008 to March 2017 and was one of the leading members in the clinical development of multiple blockbuster drugs including REVLIMID®, which is among the best-selling oncology therapies worldwide. Dr. Mei was also involved in the clinical development of POMALYST®, another one of the best-selling oncology drugs worldwide, and IDHIFA®, a first-in-class drug for the treatment of acute myeloid leukemia (AML). From April 2006 to October 2008, Dr. Mei worked as a Senior Director at Novartis Oncology, part of the Innovative Medicines division of Novartis AG (a company listed on the SIX Swiss Exchange and the New York Stock Exchange with stock codes NOVN.SIX and NVS.NYSE, respectively). In February 2001, Dr. Mei joined as a Principal Scientist in the oncology team in the drug discovery division and an Associate Director at Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Before joining the industry in 2001, Dr. Mei spent 8 years at the National Cancer Institute (part of the NIH) as a Senior Cancer Researcher. Dr. Mei was a Director of Jiangsu Asieris Pharmaceuticals Co., Ltd. (江蘇亞虹醫藥科技有限公司) from November 2014 to December 2020. Dr. Mei has been leading the management of Antengene Corporation Co., Ltd. (德琪(浙江)醫藥科技有限公司) ("**Antengene Zhejiang**") since April 2017. Dr. Mei was appointed as an Independent Director of SanReno Therapeutics Holding Limited on Feb 24, 2022.

Dr. Mei received his Doctor of Medicine degree in medicine from Hunan Medical University (湖南醫科大學) (now XiangYa School of Medicine of Central South University (中南大學湘雅醫學院)) in July 1989. Dr. Mei obtained his Doctor of Philosophy degree in pharmacology and toxicology from the University of Maryland in January 1994. Dr. Mei was a member of the American Society of Clinical Oncology and has also been a member of the American Society of Hematology since 2006. In addition, Dr. Mei currently holds an adjunct professorship at the Baruch S. Blumberg Institute.

Mr. John F. Chin, MBA, aged 56, was appointed as the CBO on January 2, 2020 and as an Executive Director on August 18, 2020. Mr. Chin has been in charge of the overall business development and commercial strategies and planning of our Group since he joined us.

Mr. Chin started his career at Merck, Sharp, and Dohme Corp in 1990 and later joined Bristol-Myers Squibb (a company listed on the New York Stock Exchange with stock code BMY.NYSE) in January 1992 to July 1998, holding a number of sales and training positions at BMS. Since October 1998, he served in a number of positions at Aventis Pharmaceutical Holdings Inc. ("**Aventis**") (before the merger in 1999, Rhône-Poulenc Rorer), including Associate Product Manager, Product Manager, Senior Product Manager for oncology and Regional Director for oncology. From January 2005 to January 2020, Mr. Chin served in a number of positions at Celgene (now part of Bristol-Myers Squibb (a company listed on the New York Stock Exchange with stock code BMY.NYSE)), including Senior Director for corporate account management, Executive Director for oncology marketing, Regional General Manager for Latin America and General Manager for China.

Mr. Chin received his Bachelor's degree in science from the University of Arizona in December 1989. He also obtained his Master's degree in business administration from Pepperdine University in April 1998.

Dr. Kevin Patrick Lynch, M.D., aged 57, was appointed as the Chief Medical Officer (CMO) in March 2021 and an Executive Director on June 18, 2021. The appointment followed an 18-month period as Consultant Chief Medical Expert to Antengene. Dr. Lynch has been in charge of the overall medical development and strategic planning of our Group since he joined us full-time.

Dr. Lynch has almost 30 years of experience in R&D in the pharmaceutical industry and a strong track record in clinical development and medical affairs. He was Vice President at Celgene between 2011 and 2019 where he led the clinical development and medical affairs in Europe (2011-2014) and Asia-Pacific (2014-2019). Before that, he was the Medical Director of Oncology at Novartis Pharmaceuticals Australia. Dr. Lynch has closely involved in early to late clinical development of multiple transformational cancer therapies, including Glivec®, Tasigna®, Zometa®, Femara®, Revlimid®, Pomalyst®, and Vidaza®.

Mr. Donald Andrew Lung (龍振國), J.D., MBA, aged 40, was appointed as the Chief Financial Officer (CFO) of the Company on June 8, 2020 and an Executive Director on June 18, 2021. Mr. Lung has been in charge of the overall finance of our Group since he joined us.

Mr. Lung has over 16 years of experience in investment banking and public equities. From June 2004 to November 2008, Mr. Lung worked at Goldman Sachs (Asia) L.L.C. He was then engaged in the asset management business at Pine River Capital Management from August 2012 to June 2017 and at Myriad Asset Management Limited from August 2017 to August 2019. From October 2019 to June 2020, Mr. Lung worked as a Portfolio Manager at BFAM Partners (Hong Kong) Limited.

Mr. Lung received his Bachelor of Arts degree in economics and political science from Yale University in May 2004. He also obtained a Master's degree in business administration and a Juris Doctor degree from The Chinese University of Hong Kong, both in November 2015.

NON-EXECUTIVE DIRECTORS

Mr. Yilun Liu (劉逸倫), MBA, aged 36, was appointed as a Non-executive Director on December 16, 2021. Mr. Liu is primarily responsible for participating in formulating our Company's corporate and business strategies.

Mr. Liu has been a Director of Keymed Biosciences Inc.(康諾亞生物醫藥科技有限公司) since March 3, 2021, and was re-designated as a Non-executive Director on April 3, 2021. He participates in decision-making in respect of major matters such as corporate and business strategies. Mr. Liu has experience working in the financial industry, including serving as the head of special situation at Anatole Investment Management Limited (晨曦投資管理有限公司). Since April 2018, Mr. Liu has been an Executive Director at Boyu Capital.

Mr. Liu received his bachelor of science degree in marketing from Fudan University (復旦大學) in the PRC in July 2009. He then obtained his master of business administration degree from Columbia Business School in May 2015.

Dr. Kan Chen (陳侃), Ph.D., aged 40, was appointed as a Non-executive Director on March 26, 2021. Dr. Chen is primarily responsible for participating in formulating our Company's corporate and business strategies.

Dr. Chen is currently serving as a Partner at Qiming Venture Partners ("**Qiming**"), focusing on healthcare investment. Dr. Chen joined Qiming in February 2016, had served as Associate and Vice President, Principal and was deeply involved in Qiming's investment of the Company's Series A Financing. Dr. Chen is currently an executive director of Jiujiuwang Food International Limited, a company listed on the Main Board of the Stock Exchange (stock code: 1927.hk) since 2019; and a non-executive director of 2 companies listed on the Main Board of the Stock Exchange, namely CANbridge Pharmaceuticals Inc. (stock code: 1228.hk) since 2020; and Datang Environment Industry Group Co., Ltd. (stock code: 1272.hk) since 2021. Dr. Chen has been a Director of Connect Biopharma Holdings Limited (a company listed on NASDAQ with stock code CNTB) since December 2020 and a Director of Asieris Pharmaceuticals (688176.SH) since December 2020. From November 2012 to September 2014, Dr. Chen has been the group leader of Jiangsu Hengrui Medicine Co., Ltd. From October 2014 to January 2016, he has been the Senior Scientist of Janssen, Pharmaceutical Companies of Johnson & Johnson.

Dr. Chen obtained his Bachelor's degree in biological science from Fudan University in June 2004. He obtained his Doctor of Philosophy degree in cell biology from Case Western Reserve University in January 2009.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Mark J. Alles, aged 63, has been serving in the capacity of an Independent Director since January 2, 2020 and was re-designated as an Independent Non-executive Director effective as of August 18, 2020.

Mr. Alles' career in the biopharmaceutical industry has spanned more than 35 years. Mr. Alles was the former Chief Executive Officer of Celgene Corporation, a global biopharmaceutical company, from March 2016 to January 2018 and Chairman and Chief Executive Officer from February 2018 until its acquisition by Bristol Myers Squibb Company in November 2019. Prior to these roles, he served as Celgene's President and Chief Operating Officer from August 2014 to February 2016 and as its Chief Commercial Officer and Executive Vice President, Haematology & Oncology from December 2012 to July 2014. Mr. Alles first joined Celgene in 2004 and served in a number of commercial management positions of increasing responsibility at the company. Mr. Alles served as the Vice President of the U.S. oncology business unit at Aventis Pharmaceuticals Inc. (Rhône-Poulenc Rorer) and served in other Senior Commercial Management roles at Aventis from 1993 to 2004.

Mr. Alles has also served as the Chairman of the board of Turning Point Therapeutics, Inc. (a precision oncology company listed on NASDAQ with stock code TPTX.NASDAQ) since May 2021, and also serves on the boards of BioMarin Pharmaceutical Inc. (a company listed on NASDAQ with stock code BMRN.NASDAQ) since December 2021 and Syros Pharmaceuticals, Inc. (a company listed on NASDAQ with stock code SYRS.NASDAQ) since December 2019.

Mr. Alles received a bachelor's degree from Lock Haven University of Pennsylvania in May 1981 and served as a Captain in the United States Marine Corps.

Ms. Jing Qian (錢晶), MBA, aged 47, is appointed as an Independent Non-executive Director effective as of November 9, 2020.

From July 1999 to July 2002, Ms. Qian served as an Associate at The Boston Consulting Group. From March 2005 to December 2008, she served as a Project Manager at McKinsey & Company. From January 2009 to March 2010, Ms. Qian was appointed as a Director responsible for business development and strategic planning for the Asia-Pacific region at Baxter (China) Investment Co., Ltd. From April 2010 to January 2012, she was appointed as a Vice President in charge of business development at Boehringer Ingelheim Pharmaceutical Co., Ltd. Ms. Qian served as the Principal at Fidelity Growth Partners Asia from January 2012 to December 2013. From February 2014 to October 2018, she was appointed as an Executive Director at FountainVest Capital. Since October 2018, Ms. Qian has been a Partner at Pivotal BioVenture Partners China, a venture capital firm specializing in venture building in the life science industry.

Ms. Qian obtained her Bachelor's degree in international economics and Master's degree in economics from East China Normal University (華東師範大學) in July 1996 and July 1999, respectively. She received her Master's degree in business administration from The Wharton School, University of Pennsylvania in May 2004.

Mr. Sheng Tang (唐晟), CPA, MBA, aged 39, is appointed as an Independent Non-executive Director effective as of November 9, 2020.

From July 2005 to July 2007, Mr. Tang performed audit and business consulting work at PricewaterhouseCoopers Zhong Tian LLP. He served as a Senior Accountant from July 2007 to September 2011 and as a Manager from October 2011 to May 2012 at Ernst & Young Hua Ming LLP Shanghai Branch. From January 2013 to January 2016, he served as a Financial Manager at CITIC Industrial Investment Group Corp., Ltd. Mr. Tang has been appointed as a Senior Lecturer at Shanghai Gaodun Financial Education Group since 2008 and was seconded to Sun Yat-Sen University and Shanghai University from March 2016 to June 2017. From September 2017 to July 2019, he served as the Chief Financial Officer at Canada Tenkey Holdings. In February 2018, Mr. Tang founded Sheng Qian Plus Corp to provide accounting and tax consulting and education services.

Mr. Tang received his Bachelor's degree in economics from Shanghai Institute of International Business and Economics (上海對外貿易學院) (now Shanghai University of International Business and Economics (上海對外經貿大學)) in July 2005 and obtained his Master's degree in business administration from Fudan University (復旦大學) in January 2015. Mr. Tang became a member of the Chinese Institute of Certified Public Accountants in June 2012. In September 2014, he was admitted as a fellow of the Association of Chartered Certified Accountants. Mr. Tang became a member of the Chartered Professional Accountants Ontario in June 2018 and a member of the Hong Kong Institute of Certified Public Accountants in July 2018.

SENIOR MANAGEMENT

Dr. Jay Mei (梅建明), M.D., Ph.D., aged 57, was appointed as a Director on August 28, 2018. He was re-designated as an Executive Director and appointed as the Chairman of the Board and the CEO on August 18, 2020. For further details of his biography, please see the sub-section headed "Executive Directors" in this section.

Mr. John F. Chin, MBA, aged 56, was appointed as the CBO on January 2, 2020 and as an Executive Director on August 18, 2020. For further details of his biography, please see the sub-section headed "Executive Directors" in this section.

Dr. Kevin Patrick Lynch, M.D., aged 57, was appointed as the Chief Medical Officer (CMO) in March 2021 and an Executive Director on June 18, 2021. For further details of his biography, please see the sub-section headed "Executive Directors" in this section.

Dr. Bo Shan (單波), Ph.D., aged 46, was appointed as the Chief Scientific Officer (CSO) of the Company in March 2021.

Dr. Shan has over 16 years of experience in R&D and manufacturing in Europe and China. Before that, he was a Corporate Vice President of the Company. During his tenure, Dr. Shan assembled highly effective discovery, CMC and manufacturing teams, and built a preclinical pipeline of 6 assets for the Company. Dr. Shan was also responsible for supporting regulatory submissions related to drug products and drug substances. Prior to joining the Company, Dr. Shan oversaw the construction and validation of Ascletis Pharma's Shaoxing production facility which successfully passed CFDA GMP inspection in 2018 as well as production, quality, sourcing, EHS and engineering departments.

Dr. Shan holds a Ph.D. in Medicinal Chemistry from Aston University in the UK.

Mr. Donald Andrew Lung (龍振國), J.D., MBA, aged 40, was appointed as the Chief Financial Officer (CFO) of the Company on June 8, 2020 and an Executive Director on June 18, 2021. For further details of his biography, please see the sub-section headed "Executive Directors" in this section.

OTHER INFORMATION

COMPLIANCE WITH CORPORATE GOVERNANCE CODE ("CG CODE")

The Company has adopted the CG Code as set out in Part 2 of Appendix 14 to the Listing Rules. In the opinion of the Directors, the Company has fully complied with CG Code during the six months ended June 30, 2022, except for the deviation from the Code Provision C.2.1 of the CG Code.

Dr. Jay Mei ("**Dr. Mei**"), the founder of our Company, Chairman of our Board and CEO, currently performs Chairman (the "**Chairman**") of the Board and chief executive officer ("**CEO**") of the Group. Under Code Provision C.2.1 of Appendix 14 to the Listing Rules, the roles of chairman and CEO should be separated and should not be performed by the same individual. Taking into account Dr. Mei's experience, personal profile and his roles in our Company, the Board considered that the roles of Chairman and CEO being performed by Dr. Mei enables more effective execution of strategic initiatives and facilitate the flow of information between management and the Board. In order to maintain good corporate governance and fully comply with the provisions of the CG Code, the Board will regularly review the need to appoint different individuals to perform the roles of Chairman and CEO separately.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS (THE "MODEL CODE")

The Company has adopted the Model Code as set out in Appendix 10 to the Listing Rules. Specific enquiries have been made of all the Directors and they have confirmed that they have complied with the Model Code throughout the Reporting Period.

The Company's employees, who are likely to be in possession of unpublished inside information of the Company, are subject to the Model Code. No incident of non-compliance of the Model Code by the employees was noted by the Company throughout the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period, the Company repurchased 1,300,000 shares on the Stock Exchange for an aggregate consideration of approximately HK$12.0 million before expenses. All of the repurchased shares were subsequently cancelled. Details of the share repurchased are as follows:

		Price paid per share		
Month of Repurchase during the Reporting Period	**No. of Shares Repurchased**	**Highest price paid** (HK$)	**Lowest price paid** (HK$)	**Aggregate consideration paid** (HK$)
January 2022	1,300,000	9.61	9.07	12,028,265
Total	1,300,000			12,028,265

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's securities listed on the Stock Exchange during the Reporting Period.

OTHER INFORMATION

USE OF NET PROCEEDS

The shares of the Company were listed on the Main Board of the Stock Exchange on November 20, 2020 (the "**Listing Date**"). The Group received net proceeds (after deduction of underwriting commissions and related costs and expenses) from the IPO and the exercise of over-allotment option of approximately RMB2,274.70 million.

The net proceeds from the listing (adjusted on a pro rata basis based on the actual net proceeds) have been and will be utilized in accordance with the Purposes set out in the Prospectus of the Company dated November 9, 2020. The table below sets out the planned allocations of the net proceeds and actual usage up to June 30, 2022:

Function	% of use of proceeds (Approximately)	Net proceeds from the HK IPO RMB million	Unutilised net proceeds as at December 31, 2021 RMB million	Actual usage during the six months ended June 30, 2022 RMB million	Unutilized net proceeds as at June 30, 2022 RMB million	Expected timeline for application of the unutilized net proceeds
Fund ongoing and planned clinical trials and milestone payments of our two Core Products and commercial launches of ATG-010	41%	932.63	592.46	158.85	433.61	Expected to be fully utilized by December 31, 2024
Fund ongoing and planned clinical trials and milestone payments of four other clinical-stage drug candidates in our pipeline	25%	568.67	524.08	12.79	511.29	Expected to be fully utilized by December 31, 2024
Fund ongoing pre-clinical studies and planned clinical trials for other pre-clinical drug candidates in our pipeline	9%	204.72	58.30	58.30	–	N/A
For expansion of our pipeline, including discovery of new drug candidates and business development activities	14%	318.46	286.48	11.67	274.81	Expected to be fully utilized by December 31, 2024
For capital expenditure	1%	22.75	–	–	–	N/A
For general corporate purposes	10%	227.47	57.14	57.14	–	N/A
Total	**100%**	**2,274.70**	**1,518.46**	**298.75**	**1,219.71**	

Notes:

(a) Net proceeds from the IPO were received in HKD and translated into RMB for the allocation and the utilization calculation, and have been adjusted slightly due to the fluctuation of the foreign exchange rates since the listing.

(b) The expected timeline was based on the Company's estimation of future market conditions and business operations, remains subject to change based on actual research and development progress, market conditions and business needs. The unutilized net proceeds of RMB1,219.71 million as at June 30, 2022 are expected to be completely used by December 31, 2024.

OTHER INFORMATION

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As far as the Company is aware, as at June 30, 2022, the interests and short positions of our Directors and chief executives in the shares, underlying shares or debentures of the Company or any of our associated corporations (within the meaning of Part XV of the SFO), which were required (a) to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO); or (b) pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (c) to be notified to the Company and the Hong Kong Stock Exchange pursuant to the Model Code, were as follows:

Name of Director or CEO	Nature of Interest	Total number of shares/underlying shares	Approximate Percentage of Shareholding Interest[2]
Dr. Jay Mei[3]	Interest in controlled corporation and beneficial interest	180,597,994(L)[1]	27.18%
Mr. John F. Chin[4]	Beneficial interest	1,515,496(L)[1]	0.23%
Mr. Donald Andrew Lung[5]	Beneficial interest	3,600,000(L)[1]	0.54%
Dr. Kevin Patrick Lynch[6]	Beneficial interest	320,000(L)[1]	0.05%
Mr. Mark J. Alles[7]	Beneficial interest	785,496(L)[1]	0.12%
Ms. Jing Qian[8]	Beneficial interest	30,000(L)[1]	0.00%
Mr. Sheng Tang[9]	Beneficial interest	30,000(L)[1]	0.00%

Notes:

(1) "L" means holding a long position in Shares.

(2) Refers to the percentage of the number of relevant Shares involved divided by the number of Shares in issue of the Company as at June 30, 2022.

(3) Meiland holds 175,927,994 Shares. Dr. Jay Mei is deemed to be interested in the total number of Shares held by Meiland. In addition, Dr. Jay Mei is entitled to acquire up to 4,670,000 Shares pursuant to the share options granted to him, subject to the relevant conditions (including the vesting conditions) thereunder.

(4) Mr. John F. Chin directly holds 135,496 Shares. In addition, Mr. John F. Chin is entitled to acquire up to 1,380,000 Shares pursuant to the share options granted to him, subject to the relevant conditions (including the vesting conditions) thereunder.

(5) Mr. Donald Andrew Lung is entitled to acquire up to 3,600,000 Shares pursuant to the share options granted to him, subject to the relevant conditions (including the vesting conditions) thereunder.

(6) Dr. Kevin Patrick Lynch is entitled to acquire up to 320,000 Shares pursuant to the share options granted to him, subject to the relevant conditions (including the vesting conditions) thereunder.

(7) Mr. Mark J. Alles directly holds 135,496 Shares. In addition, Mr. Mark J. Alles is entitled to acquire up to 650,000 Shares pursuant to the share options granted to him, subject to the relevant conditions (including the vesting conditions) thereunder.

(8) Ms. Jing Qian is entitled to acquire up to 30,000 Shares pursuant to the share options granted to her, subject to the relevant conditions (including the vesting conditions) thereunder.

(9) Mr. Sheng Tang is entitled to acquire up to 30,000 Shares pursuant to the share options granted to him, subject to the relevant conditions (including the vesting conditions) thereunder.

Save as disclosed above, as at June 30, 2022, none of the Directors or chief executives of the Company had or was deemed to have any interest or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of the Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO); or which were required to be recorded in the register to be kept by the Company pursuant to Section 352 of the SFO; or which were required, pursuant to the Model Code as contained in Appendix 10 to the Listing Rules, to be notified to the Company and the Hong Kong Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSON'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2022, to the best of the knowledge of the Company and the Directors, the following are the persons, other than the Directors or chief executives of the Company, who had interests or short positions in the shares and underlying shares of the Company which were required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were required to be entered in the register of interests required to be kept by the Company pursuant to Section 336 of Part XV of the SFO.

OTHER INFORMATION

Interests in the Shares and Underlying Shares of the Company

Name of Shareholder	Nature of Interest	Total number of shares/ underlying shares	Approximate Percentage of Shareholding Interest[2]
JAY MEI 2020 GRAT[3]	Interest in controlled corporation	175,927,994(L)[1]	26.48%
Meiland Pharma Tech SPC[3]	Beneficial interest	175,927,994(L)[1]	26.48%
Boyu Capital Group Holdings Ltd.[4]	Interest in controlled corporation	73,789,650(L)[1]	11.11%
Boyu Capital General Partner III, Ltd.[4]	Interest in controlled corporation	62,711,436(L)[1]	9.44%
Boyu Capital General Partner III, L.P.[4]	Interest in controlled corporation	62,711,436(L)[1]	9.44%
Boyu Capital Fund III, L.P.[4]	Interest in controlled corporation	62,711,436(L)[1]	9.44%
Active Ambience Limited[4]	Beneficial interest	62,711,436(L)[1]	9.44%
FMR LLC[5]	Interest in controlled corporation	53,067,578(L)[1]	7.99%
FountainVest China Capital Partners GP3 Ltd.[6]	Interest in controlled corporation	46,975,396(L)[1]	7.07%
FountainVest China Capital Partners Fund III, L.P.[6]	Interest in controlled corporation	46,975,396(L)[1]	7.07%
Begonia Investment Ltd.[6]	Beneficial interest	46,975,396(L)[1]	7.07%
TCT (BVI) Limited[7]	Interest in controlled corporation	45,702,232(L)[1]	6.88%
THE CORE TRUST COMPANY LIMITED[7]	Trustee	45,702,232(L)[1]	6.88%
FIDELITY INVESTMENT TRUST	Beneficial interest	39,768,935(L)[1]	5.99%
Qiming Corporate GP V, Ltd[8]	Interest in controlled corporation	40,170,422(L)[1]	6.05%
Qiming GP V, L.P.[8]	Interest in controlled corporation	38,961,648(L)[1]	5.86%
Qiming Venture Partners V, L.P.[8]	Beneficial interest	38,961,648(L)[1]	5.86%

Notes:

(1) "L" means holding a long position in Shares.

(2) Refers to the percentage of the number of relevant Shares involved divided by the number of Shares in issue of the Company as at June 30, 2022.

(3) Meiland Pharma Tech SC holds 175,927,994 Shares and is owned as to 75% by JAY MEI 2020 GRAT. Accordingly, JAY MEI 2020 GRAT is deemed to be interested in the total number of Shares held by Meiland Pharma Tech SC.

(4) Active Ambience Limited ("**Active Ambience**") is wholly-owned by Boyu Capital Fund III, L.P. ("**BCF III**"). Boyu Capital General Partner III, L.P. ("**BCGP III LP**") is the general partner of BCF III. Boyu Capital General Partner III, Ltd. ("**BCGP III Ltd**") is the general partner of BCGP III LP. Boyu Capital Group Holdings Ltd. ("**BCGH**") wholly-owns BCGP III Ltd. Accordingly, each of BCF III, BCGP III LP, BCGP III Ltd and BCGH is deemed to be interested in the total number of Shares held by Active Ambience. In addition, Supercluster Universe Limited ("**Supercluster Universe**") holds 3,538,714 Shares. Supercluster Universe is wholly-owned by Boyu Capital Opportunities Master Fund ("**BCOMF**"), which is in turn wholly-owned by Boyu Capital Investment Management Limited ("**BCIM**"). BCIM is wholly-owned by BCGH. Accordingly, BCGH is also deemed to be interested in the total number of Shares held by Supercluster Universe and 7,539,500 Shares directly held by BCOMF.

(5) 39,716,572 Shares, 6,661,882 Shares, 6,162,111 Shares and 527,013 Shares are directly held by Fidelity Management & Research Company LLC ("**FMRCL**"), Fidelity Management & Research (Hong Kong) ("**FMRL**"), Fidelity Institutional Asset Management Trust Company ("**FIAMTC**") and Fidelity Management Trust Company ("**FMTC**"), respectively. FMRL is wholly-owned by FMRCL. Each of FMRCL and FIAMTC is wholly-owned by FMR LLC. FIAMTC is wholly-owned by FIAM Holdings LLC, which is in turn wholly-owned by FMR LLC. Accordingly, FMR LLC is deemed to be interested in the Shares held by FMRCL, FMRL, FIAMTC and FMTC.

(6) Begonia Investment Ltd. ("**Begonia**") is owned as to 76.25% by FountainVest China Capital Partners Fund III, L.P., which is controlled by its sole shareholder, FountainVest China Capital Partners GP3 Ltd. Accordingly, each of FountainVest China Capital Partners Fund III, L.P. and FountainVest China Capital Partners GP3 Ltd. is deemed to be interested in the total number of Shares held by Begonia.

(7) THE CORE TRUST COMPANY LIMITED, as a trustee, holds 20,000,000 Shares and 25,702,232 Shares on trust under certain equity incentive plans through ATG Incentives Holding Limited and ATG Incentives Holding Plus Limited (each a "**Nominee**" and collectively "**Nominees**"), respectively. Each of the Nominees is wholly-owned by TCT (BVI) Limited, which is in turn wholly-owned by THE CORE TRUST COMPANY LIMITED.

(8) Qiming GP V, L.P. is the general partner of Qiming Venture Partners V, L.P., and Qiming Corporate GP V, Ltd is the general partner of Qiming GP V, L.P. Accordingly, each of Qiming GP V, L.P. and Qiming Corporate GP V, Ltd is deemed to be interested in the total number of Shares held by Qiming Venture Partners V, L.P. In addition, Qiming Managing Directors Fund V, L.P. holds 1,208,794 Shares. Qiming Corporate GP V, Ltd is the general partner of Qiming Managing Directors Fund V, L.P. and is deemed to be interested in the total number of Shares held by the latter.

Save as disclosed above, as at June 30, 2022, the Directors and the chief executives of the Company were not aware of any other person (other than the Directors or chief executives of the Company) who had an interest or short position in the shares or underlying shares of the Company which were required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were required to be entered in the register required to be kept by the Company pursuant to Section 336 of the SFO.

EQUITY INCENTIVE PLANS

The 2019 Equity Incentive Plan was adopted and approved by resolutions in writing by the Board on December 30, 2019 and amended by resolutions in writing by the Board on August 18, 2020. The 2020 Equity Incentive Plan was adopted and approved by resolutions in writing by the Board on August 18, 2020. The terms of the 2019 Equity Incentive Plan and the 2020 Equity Incentive Plan (collectively, the "**Equity Incentive Plans**") are substantially similar and are compliant with the provisions of Chapter 17 of the Listing Rules.

OTHER INFORMATION

As at June 30, 2022, share options to acquire an aggregate of 18,018,792 Shares, representing approximately 2.71% of the total issued share capital of the Company, are outstanding under the 2019 Equity Incentive Plan, and share options to acquire an aggregate of 17,180,220 Shares, representing approximately 2.59% of the total issued share capital of the Company, are outstanding under the 2020 Equity Incentive Plan. As at June 30, 2022, none of the share options granted under the Equity Incentive Plans has been exercised.

As at June 30, 2022, the grantees under the Equity Incentive Plans include seven Directors, two members of the senior management and 143 other employees of our Group. Details of the share options granted under the Equity Incentive Plans as at June 30, 2022 are set out below:

Name or category of grantee	Position held with the group	Outstanding As at January 1, 2022	Granted during the Reporting Period	Exercised during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding As at June 30, 2022	Date of Grant	Exercise Price	Vesting Period
Dr. Jay Mei	Executive Director, Chairman of the Board and CEO	4,000,000	–	–	–	–	4,000,000	23-Aug-20	US$0.92	Note 1
		670,000	–	–	–	–	670,000	27-Aug-21	HK$12.56	Note 3
Mr. John F. Chin	Executive Director and CBO	1,000,000	–	–	–	–	1,000,000	23-Aug-20	US$0.92	Note 3
		300,000	–	–	–	–	300,000	19-Jan-21	HK$20.65	Note 3
		80,000	–	–	–	–	80,000	27-Aug-21	HK$12.56	Note 3
Dr. Kevin Patrick Lynch	Executive Director and CMO	20,000	–	–	–	–	20,000	23-Aug-20	US$1.42	Note 3
		300,000	–	–	–	–	300,000	27-Aug-21	HK$12.56	Note 3
Mr. Donald Andrew Lung	Executive Director and CFO	3,200,000	–	–	–	–	3,200,000	23-Aug-20	US$1.42	Note 3
		300,000	–	–	–	–	300,000	19-Jan-21	HK$20.65	Note 3
		100,000	–	–	–	–	100,000	27-Aug-21	HK$12.56	Note 3
Mr. Mark J. Alles	Independent Non-executive Director	600,000	–	–	–	–	600,000	23-Aug-20	US$0.92	Note 3
		50,000	–	–	–	–	50,000	27-Aug-21	HK$12.56	Note 3

Name or category of grantee	Position held with the group	Outstanding As at January 1, 2022	Granted during the Reporting Period	Exercised during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding As at June 30, 2022	Date of Grant	Exercise Price	Vesting Period
Ms. Jing Qian	Independent Non-executive Director	20,000	–	–	–	–	20,000	23-Aug-20	US$0.92	Note 3
		10,000	–	–	–	–	10,000	27-Aug-21	HK$12.56	Note 3
Mr. Sheng Tang	Independent Non-executive Director	20,000	–	–	–	–	20,000	23-Aug-20	US$0.92	Note 3
		10,000	–	–	–	–	10,000	27-Aug-21	HK$12.56	Note 3
Mr. Yiteng Liu	COO	1,851,500	–	–	–	–	1,851,500	23-Aug-20	US$0.92	Note 1
		400,000	–	–	–	–	400,000	30-Oct-20	US$0.92	Note 1
		300,000	–	–	–	–	300,000	19-Jan-21	HK$20.65	Note 3
		100,000	–	–	–	–	100,000	27-Aug-21	HK$12.56	Note 3
Mr. Bo Shan	CSO	1,020,000	–	–	–	–	1,020,000	1-Nov-19	US$0.88	Note 2
		600,000	–	–	–	–	600,000	23-Aug-20	US$1.06	Note 3
		400,000	–	–	–	–	400,000	19-Jan-21	HK$20.65	Note 3
		150,000	–	–	–	–	150,000	27-Aug-21	HK$12.56	Note 3
Subtotal		15,501,500	0	0	0	0	15,501,500			
143 other employees of the Company		691,838	–	–	160,192	–	531,646	November 1, 2019 to October 30, 2020	US$0.88	Note 3
		7,566,524	–	–	–	–	7,566,524		US$0.88	Note 2
		1,562,000	–	–	–	–	1,562,000		US$0.92	Note 3
		1,310,000	–	–	4,000	–	1,306,000		US$1.06	Note 3
		738,000	–	–	108,000	–	630,000		US$1.21	Note 3
		1,536,000	–	–	126,000	–	1,410,000		US$1.42	Note 3
		4,435,000	–	–	553,000	–	3,882,000	19-Jan-21	HK$20.65	Note 3
		2,845,142	–	–	213,800	–	2,631,342	27-Aug-21	HK$12.56	Note 3
		178,000	–	–	–	–	178,000	20-Dec-21	HK$10.29	Note 3
Subtotal		20,862,504	0	0	1,164,992	0	19,697,512			
Total		**36,364,004**	**0**	**0**	**1,164,992**	**0**	**35,199,012**			

Notes:

1. All of such options are to be vested six months after the Listing Date.

2. 15 % of such share options were vested upon the Listing Date; 15% of such options are to be vested two years from the date of grant; 30% of such options are to be vested three years from the date of grant; 40% of such options are to vested four years from the date of grant.

3. 30% of such share options are to be vested two years from the date of grant; 30% of such options are to be vested three years from the date of grant; 40% of such options are to vested four years from the date of grant.

For further details, please refer to the section headed "Appendix IV – Statutory and General Information – Equity Incentive Plans" of the Prospectus, and note 16 to the Interim Condensed Consolidated Financial Information of this report.

2022 RSU SCHEME

On January 21, 2022, the Board has resolved to adopt the 2022 RSU Scheme, which is in parallel with other share incentive schemes which have been or may be adopted by the Company.

The maximum number of awarded shares underlying the restricted share units ("**RSUs**") awarded by the Board under the 2022 RSU Scheme (i) shall not exceed 5% of the total issued share capital of the Company as at the date of adoption of the RSU Scheme (the "**Adoption Date**") (i.e. 33,284,157 Shares) and (ii) shall be subject to an annual limit of 3% of the total issued share capital of the Company at the relevant time. The maximum number of awarded shares underlying the RSUs which may be awarded to a Selected Participant under the scheme shall not exceed 1% of the issued share capital of the Company in any 12-month period. Awards lapsed in accordance with the terms of the Scheme shall not be counted for the purpose of calculating the limit.

During the Reporting Period, no Award under the 2022 RSU Scheme has been granted.

NO MATERIAL CHANGES

Save as disclosed in this interim report, during the Reporting Period, there are no material changes affecting the Company's performance that needs to be disclosed under paragraphs 32 and 40(2) of Appendix 16 to the Listing Rules.

INTERIM DIVIDEND

The Board has resolved not to declare the payment of an interim dividend for the six months ended June 30, 2022 (six months ended June 30, 2021: nil).

AUDIT COMMITTEE AND REVIEW OF INTERIM RESULTS AND INTERIM REPORT

The audit committee of the Company (the "**Audit Committee**") has jointly reviewed with the management of the Company the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results and the interim report for the six months ended June 30, 2022) of the Group. The Audit Committee considered that the risk management and internal control system to be effective and adequate and the interim results and interim report are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

In addition, the Company's external auditor, Ernst & Young, has performed an independent review of the Group's interim financial information for the six months ended June 30, 2022 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

INDEPENDENT REVIEW REPORT

Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道 979 號
太古坊一座 27 樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

To the board of directors of Antengene Corporation Limited
(Incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 38 to 60, which comprises the condensed consolidated statement of financial position of Antengene Corporation Limited (the "**Company**") and its subsidiaries (the "**Group**") as at June 30, 2022 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* ("**IAS 34**") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young
Certified Public Accountants
Hong Kong
August 30, 2022

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2022

	Notes	Six months ended June 30, 2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
REVENUE	4	**53,956**	–
Cost of sales		**(8,705)**	–
Gross profit		**45,251**	–
Other income and gains	4	**167,820**	18,135
Research and development costs		**(179,407)**	(135,333)
Selling and distribution expenses		**(90,377)**	(132)
Administrative expenses		**(85,878)**	(78,512)
Other expenses		**(1,505)**	(36,537)
Finance costs		**(355)**	(616)
LOSS BEFORE TAX	5	**(144,451)**	(232,995)
Income tax expense	6	**–**	–
LOSS FOR THE PERIOD		**(144,451)**	(232,995)
Attributable to:			
Owners of the parent		**(144,451)**	(232,995)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	8		
Basic and diluted			
–For loss for the period		**RMB (0.23)**	RMB (0.37)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended June 30, 2022

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
LOSS FOR THE PERIOD	**(144,451)**	(232,995)
OTHER COMPREHENSIVE (LOSS)/INCOME		
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(49,365)**	5,310
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	**(49,365)**	5,310
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	**(49,365)**	5,310
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	**(193,816)**	(227,685)
Attributable to:		
Owners of the parent	**(193,816)**	(227,685)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

June 30, 2022

	Notes	June 30, 2022 RMB'000 (Unaudited)	December 31, 2021 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	9	**86,817**	71,195
Right-of-use assets		**37,775**	14,916
Other intangible assets		**50,299**	3,539
Equity investments designated at fair value through other comprehensive income		**2,574**	2,574
Financial assets at fair value through profit or loss		**4,195**	4,195
Prepayments and other receivables	10	**7,023**	48,621
Total non-current assets		**188,683**	145,040
CURRENT ASSETS			
Inventories		**8,961**	2,578
Trade receivables	11	**41,132**	7,006
Prepayments and other receivables	10	**40,490**	32,495
Financial assets at fair value through profit or loss		**102**	95,737
Cash and bank balances	12	**2,150,972**	2,274,752
Total current assets		**2,241,657**	2,412,568
CURRENT LIABILITIES			
Trade payables	13	**12,029**	1,475
Other payables and accruals	14	**174,472**	147,008
Lease liabilities		**14,028**	10,879
Total current liabilities		**200,529**	159,362
NET CURRENT ASSETS		**2,041,128**	2,253,206
TOTAL ASSETS LESS CURRENT LIABILITIES		**2,229,811**	2,398,246
NON-CURRENT LIABILITIES			
Lease liabilities		**20,956**	3,933
Total non-current liabilities		**20,956**	3,933
Net assets		**2,208,855**	2,394,313
EQUITY			
Equity attributable to owners of the parent			
Share capital	15	**444**	446
Treasury shares		**(30)**	(18,758)
Reserves		**2,208,441**	2,412,625
Total equity		**2,208,855**	2,394,313

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended June 30, 2022

		Attributable to owners of the parent						
	Notes	Share capital RMB'000	Treasury Shares	Share option reserve* RMB'000	Share premium* RMB'000	Exchange fluctuation reserve* RMB'000	Accumulated losses * RMB'000	Total RMB'000
At January 1, 2022 (audited)		446	(18,758)	130,924	6,356,229	16,039	(4,090,567)	2,394,313
Loss for the period		–	–	–	–	–	(144,451)	(144,451)
Other comprehensive income for the period:								
Exchange differences on translation of foreign operations		–	–	–	–	(49,365)	–	(49,365)
Total comprehensive loss for the period		–	–	–	–	(49,365)	(144,451)	(193,816)
Equity-settled share option arrangements		–	–	18,192	–	–	–	18,192
Repurchase of ordinary shares	15	–	(9,834)	–	–	–	–	(9,834)
Cancellation of ordinary shares	15	(2)	28,562	–	(28,560)	–	–	–
At June 30, 2022 (unaudited)		444	(30)	149,116	6,327,669	(33,326)	(4,235,018)	2,208,855
At January 1, 2021 (audited)		448	(30)	89,112	6,383,316	–	(3,435,038)	3,037,808
Loss for the period		–	–	–	–	–	(232,995)	(232,995)
Other comprehensive income for the period:								
Exchange differences on translation of foreign operations		–	–	–	–	5,310	–	5,310
Total comprehensive loss for the period		–	–	–	–	5,310	(232,995)	(227,685)
Equity-settled share option arrangements		–	–	23,135	–	–	–	23,135
Exercise of share options		–	–	(689)	1,982	–	–	1,293
Transfer of share option reserve upon the forfeiture of share options		–	–	(384)	–	–	384	–
At June 30, 2021 (unaudited)		448	(30)	111,174	6,385,298	5,310	(3,667,649)	2,834,551

* These reserve accounts comprise the reserves of RMB2,208,441,000 in the condensed consolidated statement of financial position as at June 30, 2022.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended June 30, 2022

	Notes	Six months ended June 30, 2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
CASH FLOWS USED IN OPERATING ACTIVITIES			
Loss before tax:		**(144,451)**	(232,995)
Adjustments for:			
Finance costs		**355**	616
Interest income	4	**(11,042)**	(9,666)
Depreciation of property, plant and equipment		**4,491**	1,365
Depreciation of right-of-use assets		**5,948**	2,820
Amortisation of other intangible assets		**411**	185
Equity-settled share option arrangements	16	**18,192**	23,135
Foreign exchange differences, net	5	**(144,400)**	35,796
Impairment losses on financial assets		**77**	–
		(270,419)	(178,744)
Increase in inventories		**(6,383)**	(195)
Increase in trade receivables	11	**(34,203)**	–
Increase in prepayments and other receivables		**(9,691)**	(8,806)
Increase in trade payables	13	**10,554**	–
Increase/(decrease) in other payables and accruals		**52,157**	(22,547)
Net cash flows used in operating activities		**(257,985)**	(210,292)
CASH FLOWS USED IN INVESTING ACTIVITIES			
Purchases of items of property, plant and equipment		**(15,488)**	(14,492)
Purchases of other intangible assets		**(4,362)**	(3,185)
Increase in time deposits with original maturity of more than three months	12	**(251,697)**	(797,544)
Interest received		**12,830**	881
(Increase)/decrease in pledged deposits	12	**(1,491)**	16
Proceeds from disposal of financial assets at fair value through profit or loss		**95,635**	–
Purchases of financial assets at fair value through profit or loss		**–**	(32,446)
Purchases of equity investments designated at fair value through other comprehensive income		**–**	(2,161)
Net cash flows used in investing activities		**(164,573)**	(848,931)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended June 30, 2022

	Notes	Six months ended June 30, 2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
CASH FLOWS USED IN FINANCING ACTIVITIES			
Payment of lease liabilities		**(9,003)**	(3,926)
Share issue expenses		**–**	(9,902)
Repurchase of ordinary shares		**(9,834)**	–
Net cash flows used in financing activities		**(18,837)**	(13,828)
NET DECREASE IN CASH AND CASH EQUIVALENTS		**(441,395)**	(1,073,051)
Cash and cash equivalents at beginning of period		**1,314,178**	2,094,282
Effect of foreign exchange rate changes, net		**64,427**	(27,821)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	12	**937,210**	993,410
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances	12	**2,150,972**	2,806,488
Pledged deposits	12	**(5,710)**	(4,240)
Bank deposits with original maturity of more than three months when acquired	12	**(1,208,052)**	(1,808,838)
Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows		**937,210**	993,410

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

June 30, 2022

1. CORPORATE AND GROUP INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 28 August 2018. The registered office of the Company is the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company is an investing holding company. The subsidiaries of the Company were involved in the research, development and commercialisation of pharmaceutical products.

The shares of the Company have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") effective from 20 November 2020.

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended June 30, 2022 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended December 31, 2021.

2.2 CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2021, except for the adoption of the following revised International Financial Reporting Standards ("**IFRSs**") for the first time for the current period's financial information.

Amendments to IFRS 3	*Reference to the Conceptual Framework*
Amendments to IAS 16	*Property, Plant and Equipment: Proceeds before Intended Use*
Amendments to IAS 37	*Onerous Contracts – Cost of Fulfilling a Contract*
Annual Improvements to IFRSs 2018-2020	Amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16 and IAS 41

The adoption of the above amendments did not have any impact on the financial position and performance of the Group.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group has only one reportable operating segment, which is the research, development and commercialisation of pharmaceutical products. Since this is the only reportable operating segment of the Group, no further operating segment analysis thereof is presented.

Geographical information

(a) Revenue from external customers

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Greater China	**52,750**	–
Other countries/regions	**1,206**	–
	53,956	–

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	June 30,	December 31,
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Greater China	**172,239**	137,164
United States	**6,447**	1,107
Australia	**3,228**	–
	181,914	138,271

The non-current asset information above is based on the locations of the assets and excludes financial instruments.

Information about major customers

Revenue from a single customer amounting to over 10% to the total revenue of the Group in the reporting period is as follows:

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Customer A	**39,057**	N/A
Customer B	**13,693**	N/A
	52,750	N/A

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue from contracts with customers	**53,956**	–

Revenue from contracts with customers

(a) Disaggregated revenue information

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Types of goods		
Sales of pharmaceutical products	**53,956**	–
Geographical markets		
Greater China	**52,750**	–
Other countries/regions	**1,206**	–
Total revenue from contracts with customers	**53,956**	–
Timing of revenue recognition		
Goods transferred at a point in time	**53,956**	–

(b) Performance obligations

Information about the Group's performance obligations is summarised below:

Sale of pharmaceutical products

The performance obligation is satisfied upon delivery of the pharmaceutical products and payment is generally due within 60 to 90 days from the billing date.

4. REVENUE, OTHER INCOME AND GAINS (CONTINUED)

An analysis of other income and gains is as follows:

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Other income		
Government grants related to income*	**8,686**	4,155
Bank interest income	**10,593**	9,666
Other interest income from financial assets at fair value through profit or loss	**449**	–
Others	**3,692**	4,314
	23,420	18,135
Other gains		
Foreign exchange gains, net	**144,400**	–
	167,820	18,135

* Government grants include subsidies from the governments which are specifically for (i) the incentive and subsidies for research and development activities which are recognised upon compliance with the attached conditions; (ii) other government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs recognised in profit or loss in the period in which they become receivable; and (iii) the capital expenditure incurred for plant and machinery and is recognised over the useful life of the related assets.

5. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Cost of inventories sold	**8,705**	–
Depreciation of property, plant and equipment	**4,491**	1,365
Depreciation of right-of-use assets	**5,948**	2,820
Amortisation of other intangible assets	**411**	185
Lease payments not included in the measurement of lease liabilities	**857**	159
Foreign exchange differences, net	**(144,400)**	35,796
Impairment losses on financial assets	**77**	–
Employee benefit expense:		
Wages and salaries	**110,625**	50,722
Pension scheme contributions (defined contribution scheme)	**19,140**	7,528
Staff welfare expenses	**2,393**	2,350
Equity-settled share option expense	**18,192**	23,135
	150,350	83,735
Bank interest income	**10,593**	9,666
Other interest income from financial assets at fair value through profit or loss	**449**	–

6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company was not subject to tax on income or capital gains. In addition, upon payments of dividends by the Company to its shareholders, no Cayman Islands withholding tax was imposed.

British Virgin Islands

Under the current laws of the British Virgin Islands ("**BVI**"), the subsidiaries incorporated in the BVI were not subject to tax on income or capital gains. In addition, upon payments of dividends by these subsidiaries to their shareholders, no BVI withholding tax was imposed.

Hong Kong

The subsidiaries incorporated in Hong Kong were subject to income tax at the rate of 16.5% (2021: 16.5%) on the estimated assessable profits arising in Hong Kong during the period, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HK$2,000,000 (2021: HK$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% (2021: 8.25%) and the remaining assessable profits are taxed at 16.5% (2021: 16.5%).

Macau

The subsidiary incorporated in Macau was subject to income tax at the rate of 12% (2021: 12%) on the estimated assessable profits arising in Macau during the period.

Mainland China

Pursuant to the Corporate Income Tax Law of the People's Republic of China and the respective regulations (the "**CIT Law**"), the subsidiaries which operate in Mainland China were subject to CIT at a rate of 25% (2021: 25%) on the taxable income.

6. INCOME TAX (CONTINUED)

Australia

No provision for Australia profits tax has been made as the Group had no assessable profits derived from or earned in Australia during the period (2021: Nil). The subsidiary incorporated in Australia was subject to income tax at the rate of 26% (2021: 26%) on the estimated assessable profits arising in Australia during the period.

Singapore

No provision for Singapore profits tax has been made as the Group had no assessable profits derived from or earned in Singapore during the period (2021: Nil). The subsidiary incorporated in Singapore was subject to income tax at the rate of 17% (2021: 17%) on the estimated assessable profits arising in Singapore during the period.

South Korea

No provision for South Korea profits tax has been made as the Group had no assessable profits derived from or earned in South Korea during the period (2021: Nil). The subsidiary incorporated in South Korea was subject to income tax at the rate of 10% (2021: 10%) on the estimated assessable profits arising in South Korea during the period.

United States of America

The subsidiary incorporated in Delaware, the United States was subject to statutory United States federal corporate income tax at a rate of 21% (2021: 21%). It was also subject to the state income tax in Delaware at a rate of 8.7% (2021: 8.7%) during the period.

No provision for income taxation has been made for the six months ended June 30, 2022 (June 30, 2021: Nil) as the Group had no assessable profits derived from the operating entities of the Group.

7. DIVIDENDS

No dividend was paid or declared by the Company during the six months ended June 30, 2022 (June 30, 2021: Nil).

8. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amounts is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 619,056,818 (June 30, 2021: 625,480,467) in issue during the period.

No adjustment has been made to the basic loss per share amounts presented for the six months ended June 30, 2022 and 2021 in respect of a dilution as the impact of the share options outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Loss		
Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculation	**(144,451)**	(232,995)

	Number of shares Six months ended June 30,	
	2022	2021
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares in issue* during the period used in the basic and diluted loss per share calculation	**619,056,818**	625,480,467

* after considering treasury shares

9. PROPERTY, PLANT AND EQUIPMENT

During the six months ended June 30, 2022, the Group acquired assets at a cost of RMB19,812,000 (June 30, 2021: RMB12,797,000).

No assets were disposed of by the Group during the six months ended June 30, 2022 (June 30, 2021: Nil).

No impairment loss was recognised during the six months ended June 30, 2022 (June 30, 2021: Nil).

10. PREPAYMENTS AND OTHER RECEIVABLES

	June 30, 2022 RMB'000 (Unaudited)	December 31, 2021 RMB'000 (Audited)
Non-current:		
Deposits and other receivables	**2,157**	2,249
Prepayments for purchases of property, plant and equipment	**4,866**	3,262
Prepayments for purchases of other intangible assets	**–**	43,110
	7,023	48,621
Current:		
Value-added tax recoverable	**23,740**	20,340
Interest receivables	**5,621**	7,409
Amounts due from related parties	**–**	17
Prepayments	**8,236**	2,396
Deposits and other receivables	**2,893**	2,333
	40,490	32,495

Other receivables had no historical default. The financial assets included in the above balances relate to receivables were categorised in stage 1 at the end of each reporting period. In calculating the expected credit loss rate, the Group considers the historical loss rate and adjusts for forward-looking macroeconomic data. During the period, the Group estimated that the expected credit loss rate for other receivables and deposits is minimal.

The balances are interest-free and are not secured with collateral.

The Group seeks to maintain strict control over its outstanding receivables to minimise credit risk. Long ageing balances are reviewed regularly by senior management. In view of the fact that the Group's deposits and other receivables relate to a large number of diversified counterparties, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its deposits and other receivable balances.

11. TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	June 30, 2022 RMB'000 (Unaudited)	December 31, 2021 RMB'000 (Audited)
Within 3 months	**41,132**	7,006

12. CASH AND BANK BALANCES

	June 30, 2022 RMB'000 (Unaudited)	December 31, 2021 RMB'000 (Audited)
Cash and bank balances	**2,150,972**	2,274,752
Less:		
Pledged deposits (i)	**5,710**	4,219
Bank deposits with original maturity of more than three months when acquired (ii)	**1,208,052**	956,355
Cash and cash equivalents	**937,210**	1,314,178

(i) They represent pledged deposits in commercial banks for bank overdraft. None of these deposits are either past due or impaired.

(ii) They represent time deposits with initial terms of over three months when acquired in commercial banks with annual return rates ranging from 0.40% to 2.08% (2021: 0.50% to 3.35%). None of these deposits are either past due or impaired. None of these deposits are pledged.

The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Short term time deposits are made for varying periods of between one day and three months depending on the immediate cash requirements of the Group, and earn interest at the respective short term time deposit rates. The bank balances and pledged deposits are deposited with creditworthy banks with no recent history of default.

13. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	June 30, 2022 RMB'000 (Unaudited)	December 31, 2021 RMB'000 (Audited)
Within 3 months	**12,029**	1,475

The trade payables are non-interest-bearing and are normally settled on terms of two to three months.

14. OTHER PAYABLES AND ACCRUALS

	June 30, 2022 RMB'000 (Unaudited)	December 31, 2021 RMB'000 (Audited)
Amount due to related parties	**348**	348
Deferred income*	**26,335**	26,781
Payroll payable	**39,966**	40,446
Other tax payables	**4,636**	4,488
Accrued share issue expenses	**–**	3,692
Payables for purchase of property, plant and equipment	**9,238**	3,310
Other payables**	**93,949**	67,943
	174,472	147,008

* As at June 30, 2022, deferred income included the government grants related to an asset of RMB26,335,000 (December 31, 2021: RMB26,781,000) that will be recognised in profit or loss over the expected useful life of the relevant asset.

** Other payables primarily consist of accrued or invoiced but unpaid fees for services from contract research organisations ("**CROs**"), contract development manufacture organisations ("**CDMOs**") and clinical site management operators ("**SMOs**").

Other payables and accruals are unsecured, non-interest-bearing and repayable on demand. The carrying amounts of financial liabilities included in other payables and accruals as at the end of each reporting period approximate to their fair values due to their short-term maturities.

15. SHARE CAPITAL AND TREASURY SHARES

Issued and fully paid:

	As at June 30, 2022		
	Number of shares in issue	**Share capital USD'000 (Unaudited)**	**RMB equivalent RMB'000 (Unaudited)**
Ordinary shares of USD0.0001 each	**664,383,144**	**66**	**444**

	As at December 31, 2021		
	Number of shares in issue	Share capital USD'000 (Audited)	RMB equivalent RMB'000 (Audited)
Ordinary shares of USD0.0001 each	667,890,144	67	446

A summary of movements in the Company's share capital is as follows:

	Notes	Number of shares in issue	Share capital RMB'000	Treasury shares RMB'000	Share premium RMB'000	Total RMB'000
At December 31, 2021 and January 1, 2022 (audited)		667,890,144	446	(18,758)	6,356,229	6,337,917
Repurchase of ordinary shares	(a)	–	–	(9,834)	–	(9,834)
Cancellation of ordinary shares	(b)	(3,507,000)	(2)	28,562	(28,560)	–
At June 30, 2022 (unaudited)		**664,383,144**	**444**	**(30)**	**6,327,669**	**6,328,083**

Notes:

(a) During the six months ended June 30, 2022, 1,300,000 shares were repurchased by the Company at prices ranging from HKD9.07 to HKD9.61 per share and the total consideration of HKD12,028,265 (equivalent to RMB9,834,000).

(b) During the six months ended June 30, 2022, 3,507,000 shares were cancelled by the Company.

16. SHARE-BASED PAYMENTS

Equity Incentive Plans

The Company adopted the 2019 and 2020 Equity Incentive Plans on December 30, 2019 and August 18, 2020 respectively for the purpose of providing incentives and rewards to eligible participants who contributed to the success of the Group. Eligible participants of the Equity Incentive Plans may include any officers, directors, employees of the Company, and any individual consultants or advisors who render or have rendered bona fide services to the Company.

The maximum aggregate number of shares that may be issued was 20,000,000 and 25,702,232 respectively under the 2019 and 2020 Equity Incentive Plans. Subject to any restriction contained in the equity share option plan, each vested option shall not be exercisable until the later of: (i) the date such option has vested; and (ii) 30 days after the IPO, but shall be exercised within 10 years from the date of grant. The exercise price for each share ranges from USD0.88 to USD2.65 under the 2019 and 2020 Equity Incentive Plans.

The following share options were outstanding under the 2019 and 2020 Equity Incentive Plans during the six months ended June 30, 2022 and 2021:

	Six months ended June 30,			
	2022		2021	
	Weighted average exercise price USD	**Number of options**	Weighted average exercise price USD	Number of options
At January 1 (audited)	**1.34**	**36,364,004**	1.02	27,074,178
Granted during the period	**–**	**–**	2.66	6,256,000
Forfeited during the period	**1.93**	**(1,164,992)**	2.08	(605,316)
Exercised during the period	**–**	**–**	0.91	(221,000)
At June 30 (unaudited)	**1.32**	**35,199,012**	1.32	32,503,862

16. SHARE-BASED PAYMENTS (CONTINUED)

Equity Incentive Plans (continued)

The exercise prices and exercise periods of the share options outstanding as at June 30, 2022 are as follows:

Number of options '000	Exercise price USD per share	Exercise period
920	0.88	20 Dec 2020 – 31 Oct 2029
223	0.88	20 Dec 2020 – 22 Aug 2030
5,851	0.92	20 May 2021 – 22 Aug 2030
400	0.92	20 May 2021 – 29 Oct 2030
2,519	0.88	1 Nov 2021 – 31 Oct 2029
223	0.88	1 Nov 2021 – 22 Aug 2030
3,016	0.92 – 1.42	23 Aug 2022 – 22 Aug 2030
44	1.42	19 Oct 2022 – 18 Oct 2030
50	1.06 – 1.42	30 Oct 2022 – 29 Oct 2030
1,798	0.88	1 Nov 2022 – 31 Oct 2029
446	0.88	1 Nov 2022 – 22 Aug 2030
1,555	2.66	19 Jan 2023 – 18 Jan 2031
3,016	0.92 – 1.42	23 Aug 2023 – 22 Aug 2030
1,230	1.61	27 Aug 2023 – 27 Aug 2031
44	1.42	19 Oct 2023 – 18 Oct 2030
50	1.06 – 1.42	30 Oct 2023 – 29 Oct 2030
2,397	0.88	1 Nov 2023 – 31 Oct 2029
594	0.88	1 Nov 2023 – 22 Aug 2030
53	1.32	20 Dec 2023 – 20 Dec 2031
1,555	2.66	19 Jan 2024 – 18 Jan 2031
4,022	0.92 – 1.42	23 Aug 2024 – 22 Aug 2030
1,230	1.61	27 Aug 2024 – 27 Aug 2031
58	1.42	19 Oct 2024 – 18 Oct 2030
67	1.06 – 1.42	30 Oct 2024 – 29 Oct 2030
53	1.32	20 Dec 2024 – 20 Dec 2031
2,073	2.66	19 Jan 2025 – 18 Jan 2031
1,641	1.61	27 Aug 2025 – 27 Aug 2031
71	1.32	20 Dec 2025 – 20 Dec 2031
35,199		

The Group recognised the total expense of RMB18,192,000 for the six months ended June 30, 2022 in relation to share options granted by the Company (six months ended June 30, 2021: RMB23,135,000).

17. RELATED PARTY TRANSACTIONS

In addition to the transactions detailed elsewhere in the interim condensed consolidated financial information, the Group had the following transactions with related parties during the reporting periods:

Compensation of key management personnel of the Group:

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Short term employee benefits	**21,308**	21,356
Post-employment benefits	**1,395**	987
Equity-settled share option expense	**11,137**	15,648
Total compensation paid to key management personnel	**33,840**	37,991

18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, trade receivables, trade payables, financial assets included in prepayments and other receivables and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short term maturities of these instruments.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the Chief Financial Officer and the Audit Committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the Chief Financial Officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

Below is a summary of significant inputs to the valuation of financial instruments together with an analysis as at June 30, 2022.

Financial assets/ financial liabilities	Fair value hierarchy	Valuation technique	Significant input	Relationship of inputs to fair value
Unlisted fund investment, at fair value	Level 3	Recent transaction price	N/A*	N/A*
Unlisted equity investment, at fair value	Level 3	Back-solve model and hybrid method	Enterprise value	The higher enterprise value, the higher the fair value
			Time to liquidation	The shorter time to liquidation, the higher the fair value
			Risk-free interest rate	The lower risk-free interest rate, the higher the fair value
			Volatility	The lower volatility, the higher the fair value

- The investment was acquired by the Group recently. The management of the Group considered that since there was no significant change since the acquisition, the most recent transaction price is used as the best estimate of the fair value.

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

Fair value hierarchy (continued)

Assets measured at fair value

As at June 30, 2022 (unaudited)

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000 (Unaudited)	Significant observable inputs (Level 2) RMB'000 (Unaudited)	Significant unobservable inputs (Level 3) RMB'000 (Unaudited)	Total RMB'000 (Unaudited)
Wealth management products	102	–	–	102
Unlisted equity and fund investments, at fair value	–	–	6,769	6,769
	102	–	6,769	6,871

As at December 31, 2021 (audited)

	Fair value measurement using			
	Quoted prices in active markets (Level 1) RMB'000 (Audited)	Significant observable inputs (Level 2) RMB'000 (Audited)	Significant unobservable inputs (Level 3) RMB'000 (Audited)	Total RMB'000 (Audited)
Wealth management products	–	95,737	–	95,737
Unlisted equity and fund investments, at fair value	–	–	6,769	6,769
	–	95,737	6,769	102,506

19. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed financial statements were approved and authorised for issue by the Board of Directors on August 30, 2022.